메뉴 건너뛰기




Volumn 16, Issue 11, 2014, Pages 1441-1458

Immunotherapy advances for glioblastoma

Author keywords

Glioblastoma; Immune checkpoint; Immunosuppression; Immunotherapy; Vaccine

Indexed keywords

BEVACIZUMAB; BMS 936559; CANCER VACCINE; CARBOXYMETHYLCELLULOSE; DACARBAZINE; DACLIZUMAB; DENDRITIC CELL VACCINE; DURVALUMAB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMIQUIMOD; IMMUNOLOGICAL ADJUVANT; IPILIMUMAB; LABROLIZUMAB; MONOCLONAL ANTIBODY; MPDL 3280A; NIVOLUMAB; PIDILIZUMAB; PLACEBO; POLYLYSINE; RINDOPEPIMUT; SIPULEUCEL T; TEMOZOLOMIDE; TICILIMUMAB; TISAGENLECLEUCEL T; TOLL LIKE RECEPTOR AGONIST; TUMOR ANTIGEN; TUMOR ASSOCIATED ANTIGEN VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALGANCICLOVIR; VITESPEN;

EID: 84911890607     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou212     Document Type: Article
Times cited : (151)

References (259)
  • 1
    • 84891785971 scopus 로고    scopus 로고
    • Dose-dense temozolomide for newly diagnosed glioblastoma: A randomized phase III clinical trial
    • Gilbert MR, Wang M, Aldape KD, et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol. 2013;31(32):4085-4091.
    • (2013) J Clin Oncol. , vol.31 , Issue.32 , pp. 4085-4091
    • Gilbert, M.R.1    Wang, M.2    Aldape, K.D.3
  • 2
    • 84862934329 scopus 로고    scopus 로고
    • Deregulated signaling pathways in glioblastoma multiforme: Molecular mechanisms and therapeutic targets
    • Mao H, Lebrun DG, Yang J, et al. Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets. Cancer Invest. 2012;30(1):48-56.
    • (2012) Cancer Invest. , vol.30 , Issue.1 , pp. 48-56
    • Mao, H.1    Lebrun, D.G.2    Yang, J.3
  • 3
    • 84894194756 scopus 로고    scopus 로고
    • Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma
    • Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):709-722.
    • (2014) N Engl J Med. , vol.370 , Issue.8 , pp. 709-722
    • Chinot, O.L.1    Wick, W.2    Mason, W.3
  • 4
    • 84894114159 scopus 로고    scopus 로고
    • A randomized trial of bevacizumab for newly diagnosed glioblastoma
    • Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699-708.
    • (2014) N Engl J Med. , vol.370 , Issue.8 , pp. 699-708
    • Gilbert, M.R.1    Dignam, J.J.2    Armstrong, T.S.3
  • 5
    • 77955066199 scopus 로고    scopus 로고
    • Sipuleucel-T immunotherapy for castration-resistant prostate cancer
    • Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411-422.
    • (2010) N Engl J Med. , vol.363 , Issue.5 , pp. 411-422
    • Kantoff, P.W.1    Higano, C.S.2    Shore, N.D.3
  • 6
    • 77954801079 scopus 로고    scopus 로고
    • Improved survival with ipilimumab in patients with metastatic melanoma
    • Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-723.
    • (2010) N Engl J Med. , vol.363 , Issue.8 , pp. 711-723
    • Hodi, F.S.1    O'Day, S.J.2    McDermott, D.F.3
  • 7
    • 84862903106 scopus 로고    scopus 로고
    • Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
    • Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455-2465.
    • (2012) N Engl J Med. , vol.366 , Issue.26 , pp. 2455-2465
    • Brahmer, J.R.1    Tykodi, S.S.2    Chow, L.Q.3
  • 8
    • 84862859820 scopus 로고    scopus 로고
    • Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
    • Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-2454.
    • (2012) N Engl J Med. , vol.366 , Issue.26 , pp. 2443-2454
    • Topalian, S.L.1    Hodi, F.S.2    Brahmer, J.R.3
  • 9
    • 84876325876 scopus 로고    scopus 로고
    • Chimeric antigen receptor-modified T cells for acute lymphoid leukemia
    • Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509-1518.
    • (2013) N Engl J Med. , vol.368 , Issue.16 , pp. 1509-1518
    • Grupp, S.A.1    Kalos, M.2    Barrett, D.3
  • 10
    • 84863337890 scopus 로고    scopus 로고
    • B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
    • Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119(12):2709-2720.
    • (2012) Blood , vol.119 , Issue.12 , pp. 2709-2720
    • Kochenderfer, J.N.1    Dudley, M.E.2    Feldman, S.A.3
  • 11
    • 0034754259 scopus 로고    scopus 로고
    • Fever and cancer in perspective
    • Hobohm U. Fever and cancer in perspective. Cancer Immunol Immunother. 2001;50:391-396.
    • (2001) Cancer Immunol Immunother , vol.50 , pp. 391-396
    • Hobohm, U.1
  • 12
    • 0000161413 scopus 로고
    • The treatment of malignant tumors by repeated inoculations of Erysipelas, with a report of ten original cases
    • Coley WB. The treatment of malignant tumors by repeated inoculations of Erysipelas, with a report of ten original cases. Am J Med Sci. 1893;105:487-511.
    • (1893) Am J Med Sci. , vol.105 , pp. 487-511
    • Coley, W.B.1
  • 13
    • 0014066035 scopus 로고
    • Spontaneous regression of malignant disease: Report of three cases
    • Margolis J, West D. Spontaneous regression of malignant disease: report of three cases. J Am Geriatr Soc. 1967;15(3):251-253.
    • (1967) J Am Geriatr Soc. , vol.15 , Issue.3 , pp. 251-253
    • Margolis, J.1    West, D.2
  • 14
    • 80053641609 scopus 로고    scopus 로고
    • Postoperative infection may influence survival in patients with glioblastoma: Simply a myth?
    • discussion 868-869
    • De Bonis P, Albanese A, Lofrese G, et al. Postoperative infection may influence survival in patients with glioblastoma: simply a myth?. Neurosurg. 2011;69(4):864-868. discussion 868-869.
    • (2011) Neurosurg , vol.69 , Issue.4 , pp. 864-868
    • De Bonis, P.1    Albanese, A.2    Lofrese, G.3
  • 15
    • 67650071214 scopus 로고    scopus 로고
    • IgE, allergy, and risk of glioma: Update from the San Francisco Bay Area Adult Glioma Study in the temozolomide era
    • Wiemels JL, Wilson D, Patil C, et al. IgE, allergy, and risk of glioma: update from the San Francisco Bay Area Adult Glioma Study in the temozolomide era. Int J Cancer. 2009;125(3):680-687.
    • (2009) Int J Cancer , vol.125 , Issue.3 , pp. 680-687
    • Wiemels, J.L.1    Wilson, D.2    Patil, C.3
  • 16
    • 35548956467 scopus 로고    scopus 로고
    • Atopy and risk of brain tumors: A meta-analysis
    • Linos E, Raine T, Alonso A, et al. Atopy and risk of brain tumors: a meta-analysis. J Natl Cancer Inst. 2007;99(20):1544-1550.
    • (2007) J Natl Cancer Inst. , vol.99 , Issue.20 , pp. 1544-1550
    • Linos, E.1    Raine, T.2    Alonso, A.3
  • 17
    • 33646242019 scopus 로고    scopus 로고
    • Serum IgE, tumor epidermal growth factor receptor expression, and inherited polymorphisms associated with glioma survival
    • Wrensch M, Wiencke JK, Wiemels J, et al. Serum IgE, tumor epidermal growth factor receptor expression, and inherited polymorphisms associated with glioma survival. Cancer Res. 2006;66(8):4531-4541.
    • (2006) Cancer Res. , vol.66 , Issue.8 , pp. 4531-4541
    • Wrensch, M.1    Wiencke, J.K.2    Wiemels, J.3
  • 18
    • 84859883741 scopus 로고    scopus 로고
    • Cancer and innate immune system interactions: Translational potentials for cancer immunotherapy
    • Liu Y, Zeng G. Cancer and innate immune system interactions: translational potentials for cancer immunotherapy. J Immunother. 2012;35(4):299-308.
    • (2012) J Immunother , vol.35 , Issue.4 , pp. 299-308
    • Liu, Y.1    Zeng, G.2
  • 19
    • 78651010946 scopus 로고
    • Immunity to hemologous grafted skin: III. The fate of skin hemografts transplanted to the brain, to subcutaneous tissue, and toe the anterior chamber of the eye
    • Medawar P. Immunity to hemologous grafted skin: III. The fate of skin hemografts transplanted to the brain, to subcutaneous tissue, and toe the anterior chamber of the eye. Br J Exp Pathol. 1948;29:58-69.
    • (1948) Br J Exp Pathol. , vol.29 , pp. 58-69
    • Medawar, P.1
  • 20
    • 77951837763 scopus 로고    scopus 로고
    • Trafficking of immune cells in the central nervous system
    • Wilson EH, Weninger W, Hunter CA. Trafficking of immune cells in the central nervous system. J Clin Invest. 2010;120(5):1368-1379.
    • (2010) J Clin Invest. , vol.120 , Issue.5 , pp. 1368-1379
    • Wilson, E.H.1    Weninger, W.2    Hunter, C.A.3
  • 22
    • 0025981021 scopus 로고
    • T-lymphocyte entry into the central nervous system
    • Hickey WF, Hsu BL, Kimura H. T-lymphocyte entry into the central nervous system. J Neurosci Res. 1991;28(2):254-260.
    • (1991) J Neurosci Res. , vol.28 , Issue.2 , pp. 254-260
    • Hickey, W.F.1    Hsu, B.L.2    Kimura, H.3
  • 23
    • 33748743268 scopus 로고    scopus 로고
    • CNS immune privilege: Hiding in plain sight
    • Carson MJ, Doose JM, Melchior B, et al. CNS immune privilege: hiding in plain sight. Immunol Rev. 2006;213:48-65.
    • (2006) Immunol Rev. , vol.213 , pp. 48-65
    • Carson, M.J.1    Doose, J.M.2    Melchior, B.3
  • 24
    • 0036316548 scopus 로고    scopus 로고
    • Blood-brain barrier breakdown in septic encephalopathy and brain tumours
    • Davies DC. Blood-brain barrier breakdown in septic encephalopathy and brain tumours. J Anat. 2002;200(6):639-646.
    • (2002) J Anat. , vol.200 , Issue.6 , pp. 639-646
    • Davies, D.C.1
  • 25
    • 0036942718 scopus 로고    scopus 로고
    • Extracellular matrix and the blood-brain barrier in glioblastoma multiforme: Spatial segregation of tenascin and agrin
    • Rascher G, Fischmann A, Kroger S, et al. Extracellular matrix and the blood-brain barrier in glioblastoma multiforme: spatial segregation of tenascin and agrin. Acta Neuropathol. 2002;104(1):85-91.
    • (2002) Acta Neuropathol. , vol.104 , Issue.1 , pp. 85-91
    • Rascher, G.1    Fischmann, A.2    Kroger, S.3
  • 26
    • 60549104213 scopus 로고    scopus 로고
    • Brain antigens in functionally distinct antigen-presenting cell populations in cervical lymph nodes in MS and EAE
    • van Zwam M, Huizinga R, Melief MJ, et al. Brain antigens in functionally distinct antigen-presenting cell populations in cervical lymph nodes in MS and EAE. J Mol Med (Berl). 2009;87(3):273-286.
    • (2009) J Mol Med (Berl) , vol.87 , Issue.3 , pp. 273-286
    • Van Zwam, M.1    Huizinga, R.2    Melief, M.J.3
  • 27
    • 33751503037 scopus 로고    scopus 로고
    • T cells traffic from brain to cervical lymph nodes via the cribroid plate and the nasal mucosa
    • Goldmann J, Kwidzinski E, Brandt C, et al. T cells traffic from brain to cervical lymph nodes via the cribroid plate and the nasal mucosa. J Leuk Biol. 2006;80(4):797-801.
    • (2006) J Leuk Biol. , vol.80 , Issue.4 , pp. 797-801
    • Goldmann, J.1    Kwidzinski, E.2    Brandt, C.3
  • 28
    • 0026929035 scopus 로고
    • Drainage of brain extracellular fluid into blood and deep cervical lymph and its immunological significance
    • Cserr HF, Harling-Berg CJ, Knopf PM. Drainage of brain extracellular fluid into blood and deep cervical lymph and its immunological significance. Brain Pathol. 1992;2(4):269-276.
    • (1992) Brain Pathol. , vol.2 , Issue.4 , pp. 269-276
    • Cserr, H.F.1    Harling-Berg, C.J.2    Knopf, P.M.3
  • 29
    • 45849130520 scopus 로고    scopus 로고
    • Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brain
    • Prins RM, Shu CJ, Radu CG, et al. Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brain. Cancer Immunol Immunother. 2008;57(9):1279-1289.
    • (2008) Cancer Immunol Immunother. , vol.57 , Issue.9 , pp. 1279-1289
    • Prins, R.M.1    Shu, C.J.2    Radu, C.G.3
  • 30
    • 84865469861 scopus 로고    scopus 로고
    • T cells become licensed in the lung to enter the central nervous system
    • Odoardi F, Sie C, Streyl K, et al. T cells become licensed in the lung to enter the central nervous system. Nature. 2012;488(7413):675-679.
    • (2012) Nature. , vol.488 , Issue.7413 , pp. 675-679
    • Odoardi, F.1    Sie, C.2    Streyl, K.3
  • 31
    • 34548807135 scopus 로고    scopus 로고
    • Brain microenvironment promotes the final functional maturation of tumor-specific effector CD8+ T cells
    • Masson F, Calzascia T, Di Berardino-Besson W, et al. Brain microenvironment promotes the final functional maturation of tumor-specific effector CD8+ T cells. J Immunol. 2007;179(2):845-853.
    • (2007) J Immunol. , vol.179 , Issue.2 , pp. 845-853
    • Masson, F.1    Calzascia, T.2    Di Berardino-Besson, W.3
  • 32
    • 3242658002 scopus 로고    scopus 로고
    • Microglia phagocytose alloreactive CTL-damaged 9L gliosarcoma cells
    • Kulprathipanja NV, Kruse CA. Microglia phagocytose alloreactive CTL-damaged 9L gliosarcoma cells. J Neuroimmunol. 2004;153(1-2):76-82.
    • (2004) J Neuroimmunol. , vol.153 , Issue.1-2 , pp. 76-82
    • Kulprathipanja, N.V.1    Kruse, C.A.2
  • 33
    • 0032925357 scopus 로고    scopus 로고
    • Microglia stimulate naive T-cell differentiation without stimulating T-cell proliferation
    • Carson MJ, Sutcliffe JG, Campbell IL. Microglia stimulate naive T-cell differentiation without stimulating T-cell proliferation. J Neurosci Res. 1999;55(1):127-134.
    • (1999) J Neurosci Res. , vol.55 , Issue.1 , pp. 127-134
    • Carson, M.J.1    Sutcliffe, J.G.2    Campbell, I.L.3
  • 34
    • 61449224570 scopus 로고    scopus 로고
    • Microglia: Gatekeepers of central nervous system immunology
    • Tambuyzer BR, Ponsaerts P, Nouwen EJ. Microglia: gatekeepers of central nervous system immunology. J Leukoc Biol. 2009;85(3):352-370.
    • (2009) J Leukoc Biol. , vol.85 , Issue.3 , pp. 352-370
    • Tambuyzer, B.R.1    Ponsaerts, P.2    Nouwen, E.J.3
  • 35
    • 4043144986 scopus 로고    scopus 로고
    • Initiation of immune responses in brain is promoted by local dendritic cells
    • Karman J, Ling C, Sandor M, et al. Initiation of immune responses in brain is promoted by local dendritic cells. J Immunol. 2004;173(4):2353-2361.
    • (2004) J Immunol. , vol.173 , Issue.4 , pp. 2353-2361
    • Karman, J.1    Ling, C.2    Sandor, M.3
  • 36
    • 33748532939 scopus 로고    scopus 로고
    • The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses
    • Hussain SF, Yang D, Suki D, et al. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol. 2006;8(3):261-279.
    • (2006) Neuro Oncol. , vol.8 , Issue.3 , pp. 261-279
    • Hussain, S.F.1    Yang, D.2    Suki, D.3
  • 37
    • 80053898650 scopus 로고    scopus 로고
    • Of mice and men: Experimental autoimmune encephalitis and multiple sclerosis
    • Handel AE, Lincoln MR, Ramagopalan SV. Of mice and men: experimental autoimmune encephalitis and multiple sclerosis. Eur J Clin Inv. 2011;41(11):1254-1258.
    • (2011) Eur J Clin Inv. , vol.41 , Issue.11 , pp. 1254-1258
    • Handel, A.E.1    Lincoln, M.R.2    Ramagopalan, S.V.3
  • 38
    • 84855604775 scopus 로고    scopus 로고
    • Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment
    • Jackson C, Ruzevick J, Phallen J, et al. Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment. Clin Develop Immunol. 2011;2011:732413.
    • (2011) Clin Develop Immunol. , vol.2011 , pp. 732413
    • Jackson, C.1    Ruzevick, J.2    Phallen, J.3
  • 39
    • 33847052535 scopus 로고    scopus 로고
    • Mechanisms of malignant glioma immune resistance and sources of immunosuppression
    • Gomez GG, Kruse CA. Mechanisms of malignant glioma immune resistance and sources of immunosuppression. Gene Ther Mol Biol. 2006;10(A):133-146.
    • (2006) Gene Ther Mol Biol. , vol.10 , Issue.A , pp. 133-146
    • Gomez, G.G.1    Kruse, C.A.2
  • 40
    • 70450213189 scopus 로고    scopus 로고
    • Glioblastoma-derived mechanisms of systemic immunosuppression
    • Waziri A. Glioblastoma-derived mechanisms of systemic immunosuppression. Neurosurg Clin NA. 2010;21(1):31-42.
    • (2010) Neurosurg Clin NA. , vol.21 , Issue.1 , pp. 31-42
    • Waziri, A.1
  • 41
    • 79955640835 scopus 로고    scopus 로고
    • Mechanisms of immunomodulation in human glioblastoma
    • Avril T, Vauleon E, Tanguy-Royer S, et al. Mechanisms of immunomodulation in human glioblastoma. Immunotherapy. 2011;3(4 Suppl):42-44.
    • (2011) Immunotherapy , vol.3 , Issue.4 , pp. 42-44
    • Avril, T.1    Vauleon, E.2    Tanguy-Royer, S.3
  • 42
    • 0033398454 scopus 로고    scopus 로고
    • Immune defects observed in patients with primary malignant brain tumors
    • Dix AR, Brooks WH, Roszman TL, et al. Immune defects observed in patients with primary malignant brain tumors. J Neuroimmunol. 1999;100(1-2):216-232.
    • (1999) J Neuroimmunol. , vol.100 , Issue.1-2 , pp. 216-232
    • Dix, A.R.1    Brooks, W.H.2    Roszman, T.L.3
  • 43
    • 33645502885 scopus 로고    scopus 로고
    • Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma
    • Fecci PE, Mitchell DA, Whitesides JF, et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res. 2006;66(6):3294-3302.
    • (2006) Cancer Res. , vol.66 , Issue.6 , pp. 3294-3302
    • Fecci, P.E.1    Mitchell, D.A.2    Whitesides, J.F.3
  • 44
    • 5444230303 scopus 로고    scopus 로고
    • T lymphocyte subsets and immunoglobulins in intracranial tumor patients before and after treatment, and based on histological type of tumors
    • Kempuraj D, Devi RS, Madhappan B, et al. T lymphocyte subsets and immunoglobulins in intracranial tumor patients before and after treatment, and based on histological type of tumors. Int J Immunopath Pharmacol. 2004;17(1):57-64.
    • (2004) Int J Immunopath Pharmacol. , vol.17 , Issue.1 , pp. 57-64
    • Kempuraj, D.1    Devi, R.S.2    Madhappan, B.3
  • 45
    • 80051693219 scopus 로고    scopus 로고
    • Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide
    • Grossman SA, Ye X, Lesser G, et al. Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res. 2011;17(16):5473-5480.
    • (2011) Clin Cancer Res. , vol.17 , Issue.16 , pp. 5473-5480
    • Grossman, S.A.1    Ye, X.2    Lesser, G.3
  • 46
    • 25444471021 scopus 로고    scopus 로고
    • Impaired capacity for upregulation of MHC class II in tumor-associated microglia
    • Schartner JM, Hagar AR, Van Handel M, et al. Impaired capacity for upregulation of MHC class II in tumor-associated microglia. Glia. 2005;51(4):279-285.
    • (2005) Glia , vol.51 , Issue.4 , pp. 279-285
    • Schartner, J.M.1    Hagar, A.R.2    Van Handel, M.3
  • 47
    • 28544444135 scopus 로고    scopus 로고
    • Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors
    • Facoetti A, Nano R, Zelini P, et al. Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors. Clin Cancer Res. 2005;11(23):8304-8311.
    • (2005) Clin Cancer Res. , vol.11 , Issue.23 , pp. 8304-8311
    • Facoetti, A.1    Nano, R.2    Zelini, P.3
  • 48
    • 0026541255 scopus 로고
    • Differential expression of transforming growth factor-beta 1, -beta 2, and -beta 3 by glioblastoma cells, astrocytes, and microglia
    • Constam DB, Philipp J, Malipiero UV, et al. Differential expression of transforming growth factor-beta 1, -beta 2, and -beta 3 by glioblastoma cells, astrocytes, and microglia. J Immunol. 1992;148(5):1404-1410.
    • (1992) J Immunol. , vol.148 , Issue.5 , pp. 1404-1410
    • Constam, D.B.1    Philipp, J.2    Malipiero, U.V.3
  • 49
    • 0032741283 scopus 로고    scopus 로고
    • Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function
    • Gabrilovich DI, Ishida T, Nadaf S, et al. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res. 1999;5(10):2963-2970.
    • (1999) Clin Cancer Res. , vol.5 , Issue.10 , pp. 2963-2970
    • Gabrilovich, D.I.1    Ishida, T.2    Nadaf, S.3
  • 50
    • 0025196599 scopus 로고
    • In vitro prostaglandin E2 production by glioblastoma cells and its effect on interleukin-2 activation of oncolytic lymphocytes
    • Sawamura Y, Diserens AC, de Tribolet N. In vitro prostaglandin E2 production by glioblastoma cells and its effect on interleukin-2 activation of oncolytic lymphocytes. J Neurooncol. 1990;9(2):125-130.
    • (1990) J Neurooncol. , vol.9 , Issue.2 , pp. 125-130
    • Sawamura, Y.1    Diserens, A.C.2    De Tribolet, N.3
  • 51
    • 0028888764 scopus 로고
    • Messenger RNA expression of the immunosuppressive cytokine IL-10 in human gliomas
    • Huettner C, Paulus W, Roggendorf W. Messenger RNA expression of the immunosuppressive cytokine IL-10 in human gliomas. Am J Pathol. 1995;146(2):317-322.
    • (1995) Am J Pathol. , vol.146 , Issue.2 , pp. 317-322
    • Huettner, C.1    Paulus, W.2    Roggendorf, W.3
  • 52
    • 77953798698 scopus 로고    scopus 로고
    • Immune infiltration of spontaneous mouse astrocytomas is dominated by immunosuppressive cells from early stages of tumor development
    • Tran Thang NN, Derouazi M, Philippin G, et al. Immune infiltration of spontaneous mouse astrocytomas is dominated by immunosuppressive cells from early stages of tumor development. Cancer Res. 2010;70(12):4829-4839.
    • (2010) Cancer Res. , vol.70 , Issue.12 , pp. 4829-4839
    • Tran Thang, N.N.1    Derouazi, M.2    Philippin, G.3
  • 53
    • 0028807156 scopus 로고
    • Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro
    • discussion 1166-1167
    • Hishii M, Nitta T, Ishida H, et al. Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro. Neurosurg. 1995;37(6):1160-1166. discussion 1166-1167.
    • (1995) Neurosurg. , vol.37 , Issue.6 , pp. 1160-1166
    • Hishii, M.1    Nitta, T.2    Ishida, H.3
  • 54
    • 34248529706 scopus 로고    scopus 로고
    • Malignant glioma cells counteract antitumor immune responses through expression of lectin-like transcript-1
    • Roth P, Mittelbronn M, Wick W, et al. Malignant glioma cells counteract antitumor immune responses through expression of lectin-like transcript-1. Cancer Res. 2007;67(8):3540-3544.
    • (2007) Cancer Res. , vol.67 , Issue.8 , pp. 3540-3544
    • Roth, P.1    Mittelbronn, M.2    Wick, W.3
  • 55
    • 52649169692 scopus 로고    scopus 로고
    • Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas
    • Heimberger AB, Abou-Ghazal M, Reina-Ortiz C, et al. Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin Cancer Res. 2008;14(16):5166-5172.
    • (2008) Clin Cancer Res. , vol.14 , Issue.16 , pp. 5166-5172
    • Heimberger, A.B.1    Abou-Ghazal, M.2    Reina-Ortiz, C.3
  • 56
    • 33748481603 scopus 로고    scopus 로고
    • An increase in CD4+CD25+ FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme
    • El Andaloussi A, Lesniak MS. An increase in CD4+CD25+ FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neuro Oncol. 2006;8(3):234-243.
    • (2006) Neuro Oncol. , vol.8 , Issue.3 , pp. 234-243
    • El Andaloussi, A.1    Lesniak, M.S.2
  • 57
    • 84860358785 scopus 로고    scopus 로고
    • Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: Implications for immunotherapy
    • Crane CA, Ahn BJ, Han SJ, et al. Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy. Neuro Oncol. 2012;14(5):584-595.
    • (2012) Neuro Oncol. , vol.14 , Issue.5 , pp. 584-595
    • Crane, C.A.1    Ahn, B.J.2    Han, S.J.3
  • 58
    • 77955658133 scopus 로고    scopus 로고
    • Prognostic significance and mechanism of Treg infiltration in human brain tumors
    • Jacobs JF, Idema AJ, Bol KF, et al. Prognostic significance and mechanism of Treg infiltration in human brain tumors. J Neuroimmunol. 2010;225(1-2):195-199.
    • (2010) J Neuroimmunol. , vol.225 , Issue.1-2 , pp. 195-199
    • Jacobs, J.F.1    Idema, A.J.2    Bol, K.F.3
  • 59
    • 0035879509 scopus 로고    scopus 로고
    • Role of microglia in glioma biology
    • Badie B, Schartner J. Role of microglia in glioma biology. Microscopy Res Tech. 2001;54(2):106-113.
    • (2001) Microscopy Res Tech. , vol.54 , Issue.2 , pp. 106-113
    • Badie, B.1    Schartner, J.2
  • 60
    • 84864709456 scopus 로고    scopus 로고
    • The molecular profile of microglia under the influence of glioma
    • Li W, Graeber MB. The molecular profile of microglia under the influence of glioma. Neuro Oncol. 2012;14(8):958-978.
    • (2012) Neuro Oncol. , vol.14 , Issue.8 , pp. 958-978
    • Li, W.1    Graeber, M.B.2
  • 61
    • 79251620102 scopus 로고    scopus 로고
    • Hypoxia potentiates glioma-mediated immunosuppression
    • Wei J, Wu A, Kong LY, et al. Hypoxia potentiates glioma-mediated immunosuppression. PloS One. 2011;6(1):e16195.
    • (2011) PloS One. , vol.6 , Issue.1 , pp. e16195
    • Wei, J.1    Wu, A.2    Kong, L.Y.3
  • 62
    • 33646879823 scopus 로고    scopus 로고
    • T-cell apoptosis in human glioblastoma multiforme: Implications for immunotherapy
    • Walker DG, Chuah T, Rist MJ, et al. T-cell apoptosis in human glioblastoma multiforme: implications for immunotherapy. J Neuroimmunol. 2006;175(1-2):59-68.
    • (2006) J Neuroimmunol. , vol.175 , Issue.1-2 , pp. 59-68
    • Walker, D.G.1    Chuah, T.2    Rist, M.J.3
  • 63
    • 77954741566 scopus 로고    scopus 로고
    • FasL gene knock-down therapy enhances the antiglioma immune response
    • Jansen T, Tyler B, Mankowski JL, et al. FasL gene knock-down therapy enhances the antiglioma immune response. Neuro Oncol. 2010;12(5):482-489.
    • (2010) Neuro Oncol. , vol.12 , Issue.5 , pp. 482-489
    • Jansen, T.1    Tyler, B.2    Mankowski, J.L.3
  • 64
    • 42649125225 scopus 로고    scopus 로고
    • PD-1 and its ligands in tolerance and immunity
    • Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Ann Rev Immunol. 2008;26:677-704.
    • (2008) Ann Rev Immunol. , vol.26 , pp. 677-704
    • Keir, M.E.1    Butte, M.J.2    Freeman, G.J.3
  • 65
    • 77953679701 scopus 로고    scopus 로고
    • Understanding and enhancing the graft-versus-leukemia effect after hematopoietic stem cell transplantation
    • Molldrem J, Riddell S. Understanding and enhancing the graft-versus-leukemia effect after hematopoietic stem cell transplantation. Ca Treat Res. 2009;144:187-208.
    • (2009) Ca Treat Res. , vol.144 , pp. 187-208
    • Molldrem, J.1    Riddell, S.2
  • 66
    • 0025678601 scopus 로고
    • Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients
    • Kolb HJ, Mittermuller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990;76(12):2462-2465.
    • (1990) Blood , vol.76 , Issue.12 , pp. 2462-2465
    • Kolb, H.J.1    Mittermuller, J.2    Clemm, C.3
  • 67
    • 77649221824 scopus 로고    scopus 로고
    • Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients
    • Heslop HE, Slobod KS, Pule MA, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010;115(5):925-935.
    • (2010) Blood , vol.115 , Issue.5 , pp. 925-935
    • Heslop, H.E.1    Slobod, K.S.2    Pule, M.A.3
  • 68
    • 0023115642 scopus 로고
    • A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone
    • Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987;316(15):889-897.
    • (1987) N Engl J Med. , vol.316 , Issue.15 , pp. 889-897
    • Rosenberg, S.A.1    Lotze, M.T.2    Muul, L.M.3
  • 69
    • 20244366111 scopus 로고    scopus 로고
    • Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma
    • Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23(10):2346-2357.
    • (2005) J Clin Oncol. , vol.23 , Issue.10 , pp. 2346-2357
    • Dudley, M.E.1    Wunderlich, J.R.2    Yang, J.C.3
  • 70
    • 0031832638 scopus 로고    scopus 로고
    • Systemic T cell adoptive immunotherapy of malignant gliomas
    • Plautz GE, Barnett GH, Miller DW, et al. Systemic T cell adoptive immunotherapy of malignant gliomas. J Neurosurg. 1998;89(1):42-51.
    • (1998) J Neurosurg , vol.89 , Issue.1 , pp. 42-51
    • Plautz, G.E.1    Barnett, G.H.2    Miller, D.W.3
  • 71
    • 0034044202 scopus 로고    scopus 로고
    • T cell adoptive immunotherapy of newly diagnosed gliomas
    • Plautz GE, Miller DW, Barnett GH, et al. T cell adoptive immunotherapy of newly diagnosed gliomas. Clin Cancer Res. 2000;6(6):2209-2218.
    • (2000) Clin Cancer Res. , vol.6 , Issue.6 , pp. 2209-2218
    • Plautz, G.E.1    Miller, D.W.2    Barnett, G.H.3
  • 72
    • 0041833713 scopus 로고    scopus 로고
    • Effects of local injection of ex vivo expanded autologous tumor-specific T lymphocytes in cases with recurrent malignant gliomas
    • Tsuboi K, Saijo K, Ishikawa E, et al. Effects of local injection of ex vivo expanded autologous tumor-specific T lymphocytes in cases with recurrent malignant gliomas. Clin Cancer Res. 2003;9(9):3294-3302.
    • (2003) Clin Cancer Res. , vol.9 , Issue.9 , pp. 3294-3302
    • Tsuboi, K.1    Saijo, K.2    Ishikawa, E.3
  • 73
    • 84856845120 scopus 로고    scopus 로고
    • Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma
    • Ghazi A, Ashoori A, Hanley PJ, et al. Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma. J Immunother. 2012;35(2):159-168.
    • (2012) J Immunother. , vol.35 , Issue.2 , pp. 159-168
    • Ghazi, A.1    Ashoori, A.2    Hanley, P.J.3
  • 74
    • 77956535599 scopus 로고    scopus 로고
    • Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor
    • Jena B, Dotti G, Cooper LJ. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood. 2010;116(7):1035-1044.
    • (2010) Blood , vol.116 , Issue.7 , pp. 1035-1044
    • Jena, B.1    Dotti, G.2    Cooper, L.J.3
  • 75
    • 80054680991 scopus 로고    scopus 로고
    • Treating cancer with genetically engineered T cells
    • Park TS, Rosenberg SA, Morgan RA. Treating cancer with genetically engineered T cells. Trends Biotechnol. 2010;29(11):550-557.
    • (2010) Trends Biotechnol. , vol.29 , Issue.11 , pp. 550-557
    • Park, T.S.1    Rosenberg, S.A.2    Morgan, R.A.3
  • 76
    • 84863085396 scopus 로고    scopus 로고
    • CAR-T cells and solid tumors: Tuning T cells to challenge an inveterate foe
    • Gilham DE, Debets R, Pule M, et al. CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe. Trends Mol Med. 2012;18(7):377-384.
    • (2012) Trends Mol Med. , vol.18 , Issue.7 , pp. 377-384
    • Gilham, D.E.1    Debets, R.2    Pule, M.3
  • 77
    • 77950475517 scopus 로고    scopus 로고
    • Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2
    • Morgan RA, Yang JC, Kitano M, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18(4):843-851.
    • (2010) Mol Ther. , vol.18 , Issue.4 , pp. 843-851
    • Morgan, R.A.1    Yang, J.C.2    Kitano, M.3
  • 78
    • 84868583378 scopus 로고    scopus 로고
    • Model T muscle CARs can treat brain tumors
    • Johnson LA. Model T muscle CARs can treat brain tumors. Clin Cancer Res. 2012;18(21):5834-5836.
    • (2012) Clin Cancer Res. , vol.18 , Issue.21 , pp. 5834-5836
    • Johnson, L.A.1
  • 79
    • 84859820456 scopus 로고    scopus 로고
    • Stem-like tumor-initiating cells isolated from IL13Ralpha2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells
    • Brown CE, Starr R, Aguilar B, et al. Stem-like tumor-initiating cells isolated from IL13Ralpha2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells. Clin Cancer Res. 2012;18(8):2199-2209.
    • (2012) Clin Cancer Res. , vol.18 , Issue.8 , pp. 2199-2209
    • Brown, C.E.1    Starr, R.2    Aguilar, B.3
  • 80
    • 84868576774 scopus 로고    scopus 로고
    • Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells
    • Kong S, Sengupta S, Tyler B, et al. Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells. Clin Cancer Res. 2012;18(21):5949-5960.
    • (2012) Clin Cancer Res. , vol.18 , Issue.21 , pp. 5949-5960
    • Kong, S.1    Sengupta, S.2    Tyler, B.3
  • 81
    • 78650721870 scopus 로고    scopus 로고
    • Synergistic therapeutic effects of cytokine-induced killer cells and temozolomide against glioblastoma
    • Jin J, Joo KM, Lee SJ, et al. Synergistic therapeutic effects of cytokine-induced killer cells and temozolomide against glioblastoma. Oncol Rep. 2011;25(1):33-39.
    • (2011) Oncol Rep. , vol.25 , Issue.1 , pp. 33-39
    • Jin, J.1    Joo, K.M.2    Lee, S.J.3
  • 82
    • 84875215925 scopus 로고    scopus 로고
    • T cells redirected to EphA2 for the immunotherapy of glioblastoma
    • Chow KK, Naik S, Kakarla S, et al. T cells redirected to EphA2 for the immunotherapy of glioblastoma. Mol Ther. 2013;21(3):629-637.
    • (2013) Mol Ther. , vol.21 , Issue.3 , pp. 629-637
    • Chow, K.K.1    Naik, S.2    Kakarla, S.3
  • 83
    • 84875198775 scopus 로고    scopus 로고
    • Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma
    • Morgan RA, Johnson LA, Davis J, et al. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum Gen Ther. 2012;23:1043-1053.
    • (2012) Hum Gen Ther. , vol.23 , pp. 1043-1053
    • Morgan, R.A.1    Johnson, L.A.2    Davis, J.3
  • 84
    • 84878931351 scopus 로고    scopus 로고
    • Targeting T cells to tumor cells using bispecific antibodies
    • Frankel SR, Baeuerle PA. Targeting T cells to tumor cells using bispecific antibodies. Curr Opin Chem Biol. 2013;17(3):385-392.
    • (2013) Curr Opin Chem Biol. , vol.17 , Issue.3 , pp. 385-392
    • Frankel, S.R.1    Baeuerle, P.A.2
  • 85
    • 79958041608 scopus 로고    scopus 로고
    • Bispecific antibodies engage Tcells for antitumor immunotherapy
    • Choi BD, Cai M, Bigner DD, et al. Bispecific antibodies engage Tcells for antitumor immunotherapy. Exp Opin Biol Ther. 2011;11(7):843-853.
    • (2011) Exp Opin Biol Ther. , vol.11 , Issue.7 , pp. 843-853
    • Choi, B.D.1    Cai, M.2    Bigner, D.D.3
  • 86
    • 79959312575 scopus 로고    scopus 로고
    • Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapyrefractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival
    • Topp MS, Kufer P, Gokbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapyrefractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29(18):2493-2498.
    • (2011) J Clin Oncol. , vol.29 , Issue.18 , pp. 2493-2498
    • Topp, M.S.1    Kufer, P.2    Gokbuget, N.3
  • 87
    • 84871965330 scopus 로고    scopus 로고
    • Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma
    • Choi BD, Kuan CT, Cai M, et al. Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma. Proc Natl Acad Sci USA. 2013;110(1):270-275.
    • (2013) Proc Natl Acad Sci USA. , vol.110 , Issue.1 , pp. 270-275
    • Choi, B.D.1    Kuan, C.T.2    Cai, M.3
  • 88
    • 34548555781 scopus 로고    scopus 로고
    • Expression of interleukin-13 receptor alpha2 in glioblastoma multiforme: Implications for targeted therapies
    • Jarboe JS, Johnson KR, Choi Y, et al. Expression of interleukin-13 receptor alpha2 in glioblastoma multiforme: implications for targeted therapies. Cancer Res. 2007;67(17):7983-7986.
    • (2007) Cancer Res. , vol.67 , Issue.17 , pp. 7983-7986
    • Jarboe, J.S.1    Johnson, K.R.2    Choi, Y.3
  • 89
    • 0025686126 scopus 로고
    • Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts
    • Bigner SH, Humphrey PA, Wong AJ, et al. Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res. 1990;50(24):8017-8022.
    • (1990) Cancer Res. , vol.50 , Issue.24 , pp. 8017-8022
    • Bigner, S.H.1    Humphrey, P.A.2    Wong, A.J.3
  • 90
    • 0021932240 scopus 로고
    • Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin
    • Libermann TA, Nusbaum HR, Razon N, et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature. 1985;313(5998):144-147.
    • (1985) Nature , vol.313 , Issue.5998 , pp. 144-147
    • Libermann, T.A.1    Nusbaum, H.R.2    Razon, N.3
  • 91
    • 0037463232 scopus 로고    scopus 로고
    • Clinical implications of quantitative real-time RT-PCR analysis of hTERT gene expression in human gliomas
    • Tchirkov A, Rolhion C, Kemeny JL, et al. Clinical implications of quantitative real-time RT-PCR analysis of hTERT gene expression in human gliomas. Brit J Cancer. 2003;88(4):516-520.
    • (2003) Brit J Cancer , vol.88 , Issue.4 , pp. 516-520
    • Tchirkov, A.1    Rolhion, C.2    Kemeny, J.L.3
  • 92
    • 0032749913 scopus 로고    scopus 로고
    • Expression of the tumor-rejection antigen SART1 in brain tumors
    • Imaizumi T, Kuramoto T, Matsunaga K, et al. Expression of the tumor-rejection antigen SART1 in brain tumors. Int J Cancer. 1999;83(6):760-764.
    • (1999) Int J Cancer , vol.83 , Issue.6 , pp. 760-764
    • Imaizumi, T.1    Kuramoto, T.2    Matsunaga, K.3
  • 93
  • 94
    • 0033049977 scopus 로고    scopus 로고
    • Expression of MAGE and GAGE in high-grade brain tumors: A potential target for specific immunotherapy and diagnostic markers
    • Scarcella DL, Chow CW, Gonzales MF, et al. Expression of MAGE and GAGE in high-grade brain tumors: a potential target for specific immunotherapy and diagnostic markers. Clin Cancer Res. 1999;5(2):335-341.
    • (1999) Clin Cancer Res. , vol.5 , Issue.2 , pp. 335-341
    • Scarcella, D.L.1    Chow, C.W.2    Gonzales, M.F.3
  • 95
    • 3142710121 scopus 로고    scopus 로고
    • HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells
    • Liu G, Ying H, Zeng G, et al. HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells. Cancer Res. 2004;64(14):4980-4986.
    • (2004) Cancer Res. , vol.64 , Issue.14 , pp. 4980-4986
    • Liu, G.1    Ying, H.2    Zeng, G.3
  • 96
    • 0036718859 scopus 로고    scopus 로고
    • ∗0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain
    • ∗0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain. Clin Cancer Res. 2002;8(9):2851-2855.
    • (2002) Clin Cancer Res. , vol.8 , Issue.9 , pp. 2851-2855
    • Okano, F.1    Storkus, W.J.2    Chambers, W.H.3
  • 97
    • 0037083317 scopus 로고    scopus 로고
    • Quantitatively determined survivin expression levels are of prognostic value in human gliomas
    • Chakravarti A, Noll E, Black PM, et al. Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol. 2002;20(4):1063-1068.
    • (2002) J Clin Oncol. , vol.20 , Issue.4 , pp. 1063-1068
    • Chakravarti, A.1    Noll, E.2    Black, P.M.3
  • 98
    • 3142692559 scopus 로고    scopus 로고
    • Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma
    • Yu JS, Liu G, Ying H, et al. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res. 2004;64(14):4973-4979.
    • (2004) Cancer Res. , vol.64 , Issue.14 , pp. 4973-4979
    • Yu, J.S.1    Liu, G.2    Ying, H.3
  • 99
    • 0035107548 scopus 로고    scopus 로고
    • Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration
    • Yu JS, Wheeler CJ, Zeltzer PM, et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res. 2001;61(3):842-847.
    • (2001) Cancer Res. , vol.61 , Issue.3 , pp. 842-847
    • Yu, J.S.1    Wheeler, C.J.2    Zeltzer, P.M.3
  • 100
    • 79951978155 scopus 로고    scopus 로고
    • Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma
    • Okada H, Kalinski P, Ueda R, et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol. 2011;29(3):330-336.
    • (2011) J Clin Oncol. , vol.29 , Issue.3 , pp. 330-336
    • Okada, H.1    Kalinski, P.2    Ueda, R.3
  • 101
    • 84872498982 scopus 로고    scopus 로고
    • Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma
    • Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother. 2013;62:125-135.
    • (2013) Cancer Immunol Immunother. , vol.62 , pp. 125-135
    • Phuphanich, S.1    Wheeler, C.J.2    Rudnick, J.D.3
  • 102
    • 0026548240 scopus 로고
    • Structural alterations of the epidermal growth factor receptor gene in human gliomas
    • Wong AJ, Ruppert JM, Bigner SH, et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA. 1992;89(7):2965-2969.
    • (1992) Proc Natl Acad Sci USA , vol.89 , Issue.7 , pp. 2965-2969
    • Wong, A.J.1    Ruppert, J.M.2    Bigner, S.H.3
  • 103
    • 84863154888 scopus 로고    scopus 로고
    • Targeting EGF receptor variant III: Tumor-specific peptide vaccination for malignant gliomas
    • Del Vecchio CA, Li G, Wong AJ. Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas. Exp Rev Vac. 2012;11(2):133-144.
    • (2012) Exp Rev Vac. , vol.11 , Issue.2 , pp. 133-144
    • Del Vecchio, C.A.1    Li, G.2    Wong, A.J.3
  • 104
    • 0141790037 scopus 로고    scopus 로고
    • Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors
    • Heimberger AB, Crotty LE, Archer GE, et al. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res. 2003;9(11):4247-4254.
    • (2003) Clin Cancer Res. , vol.9 , Issue.11 , pp. 4247-4254
    • Heimberger, A.B.1    Crotty, L.E.2    Archer, G.E.3
  • 105
    • 39149097490 scopus 로고    scopus 로고
    • Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: Case study
    • Heimberger AB, Sun W, Hussain SF, et al. Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. Neuro Oncol. 2008;10(1):98-103.
    • (2008) Neuro Oncol. , vol.10 , Issue.1 , pp. 98-103
    • Heimberger, A.B.1    Sun, W.2    Hussain, S.F.3
  • 106
    • 79955784386 scopus 로고    scopus 로고
    • Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma
    • Sampson JH, Aldape KD, Archer GE, et al. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol. 2011;13(3):324-333.
    • (2011) Neuro Oncol. , vol.13 , Issue.3 , pp. 324-333
    • Sampson, J.H.1    Aldape, K.D.2    Archer, G.E.3
  • 107
    • 70350236627 scopus 로고    scopus 로고
    • An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme
    • Sampson JH, Archer GE, Mitchell DA, et al. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther. 2009;8(10):2773-2779.
    • (2009) Mol Cancer Ther. , vol.8 , Issue.10 , pp. 2773-2779
    • Sampson, J.H.1    Archer, G.E.2    Mitchell, D.A.3
  • 108
    • 78149254368 scopus 로고    scopus 로고
    • Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma
    • Sampson JH, Heimberger AB, Archer GE, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010;28(31):4722-4729.
    • (2010) J Clin Oncol. , vol.28 , Issue.31 , pp. 4722-4729
    • Sampson, J.H.1    Heimberger, A.B.2    Archer, G.E.3
  • 109
    • 53049089002 scopus 로고    scopus 로고
    • Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines
    • Schmittling RJ, Archer GE, Mitchell DA, et al. Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines. J Immunol Meth. 2008;339(1):74-81.
    • (2008) J Immunol Meth. , vol.339 , Issue.1 , pp. 74-81
    • Schmittling, R.J.1    Archer, G.E.2    Mitchell, D.A.3
  • 111
    • 0037096733 scopus 로고    scopus 로고
    • Human cytomegalovirus infection and expression in human malignant glioma
    • Cobbs CS, Harkins L, Samanta M, et al. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res. 2002;62(12):3347-3350.
    • (2002) Cancer Res. , vol.62 , Issue.12 , pp. 3347-3350
    • Cobbs, C.S.1    Harkins, L.2    Samanta, M.3
  • 112
    • 39149136486 scopus 로고    scopus 로고
    • Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma
    • Mitchell DA, Xie W, Schmittling R, et al. Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro-oncol. 2008;10(1):10-18.
    • (2008) Neuro-oncol. , vol.10 , Issue.1 , pp. 10-18
    • Mitchell, D.A.1    Xie, W.2    Schmittling, R.3
  • 113
    • 48249102647 scopus 로고    scopus 로고
    • Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate
    • Prins RM, Cloughesy TF, Liau LM. Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate. New Engl J Med. 2008;359(5):539-541.
    • (2008) New Engl J Med. , vol.359 , Issue.5 , pp. 539-541
    • Prins, R.M.1    Cloughesy, T.F.2    Liau, L.M.3
  • 114
    • 79959834313 scopus 로고    scopus 로고
    • The detection of CMV pp65 and IE1 in glioblastoma multiforme
    • Lucas KG, Bao L, Bruggeman R, et al. The detection of CMV pp65 and IE1 in glioblastoma multiforme. J Neurooncol. 2011;103(2):231-238.
    • (2011) J Neurooncol. , vol.103 , Issue.2 , pp. 231-238
    • Lucas, K.G.1    Bao, L.2    Bruggeman, R.3
  • 115
    • 79954502340 scopus 로고    scopus 로고
    • Detection of human cytomegalovirus in normal and neoplastic breast epithelium
    • Harkins LE, Matlaf LA, Soroceanu L, et al. Detection of human cytomegalovirus in normal and neoplastic breast epithelium. Herpesviridae. 2010;1(1):8.
    • (2010) Herpesviridae , vol.1 , Issue.1 , pp. 8
    • Harkins, L.E.1    Matlaf, L.A.2    Soroceanu, L.3
  • 116
    • 82255169334 scopus 로고    scopus 로고
    • Human cytomegalovirus and mucoepidermoid carcinoma of salivary glands: Cell-specific localization of active viral and oncogenic signaling proteins is confirmatory of a causal relationship
    • Melnick M, Sedghizadeh PP, Allen CM, et al. Human cytomegalovirus and mucoepidermoid carcinoma of salivary glands: cell-specific localization of active viral and oncogenic signaling proteins is confirmatory of a causal relationship. Exp Mol Pathol. 2012;92(1):118-125.
    • (2012) Exp Mol Pathol. , vol.92 , Issue.1 , pp. 118-125
    • Melnick, M.1    Sedghizadeh, P.P.2    Allen, C.M.3
  • 117
    • 0042236661 scopus 로고    scopus 로고
    • High prevalence of human cytomegalovirus in prostatic intraepithelial neoplasia and prostatic carcinoma
    • Samanta M, Harkins L, Klemm K, et al. High prevalence of human cytomegalovirus in prostatic intraepithelial neoplasia and prostatic carcinoma. J Urol. 2003;170(3):998-1002.
    • (2003) J Urol. , vol.170 , Issue.3 , pp. 998-1002
    • Samanta, M.1    Harkins, L.2    Klemm, K.3
  • 118
    • 80053390591 scopus 로고    scopus 로고
    • Detection of human cytomegalovirus in medulloblastomas reveals a potential therapeutic target
    • Baryawno N, Rahbar A, Wolmer-Solberg N, et al. Detection of human cytomegalovirus in medulloblastomas reveals a potential therapeutic target. J Clin Invest. 2011;121(10):4043-4055.
    • (2011) J Clin Invest. , vol.121 , Issue.10 , pp. 4043-4055
    • Baryawno, N.1    Rahbar, A.2    Wolmer-Solberg, N.3
  • 119
    • 84883439743 scopus 로고    scopus 로고
    • Survival in patients with glioblastoma receiving valganciclovir
    • Soderberg-Naucler C, Rahbar A, Stragliotto G. Survival in patients with glioblastoma receiving valganciclovir. N Engl J Med. 2013;369(10):985-986.
    • (2013) N Engl J Med. , vol.369 , Issue.10 , pp. 985-986
    • Soderberg-Naucler, C.1    Rahbar, A.2    Stragliotto, G.3
  • 120
    • 84908233609 scopus 로고    scopus 로고
    • Cancer Immunology at the Crossroads: Functional Genomics Getting Personal with Neoantigen-Based Therapeutic Cancer Vaccines
    • Hacohen N, Fritsch EF, Carter TA, et al. Cancer Immunology at the Crossroads: Functional Genomics Getting Personal with Neoantigen-Based Therapeutic Cancer Vaccines. Cancer Immunol Res. 2013;1:11-15.
    • (2013) Cancer Immunol Res. , vol.1 , pp. 11-15
    • Hacohen, N.1    Fritsch, E.F.2    Carter, T.A.3
  • 121
    • 84862776855 scopus 로고    scopus 로고
    • Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
    • Matsushita H, Vesely MD, Koboldt DC, et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature. 2012;482(7385):400-404.
    • (2012) Nature , vol.482 , Issue.7385 , pp. 400-404
    • Matsushita, H.1    Vesely, M.D.2    Koboldt, D.C.3
  • 122
    • 27644534576 scopus 로고    scopus 로고
    • The response of autologous T cells to a human melanoma is dominated by mutated neoantigens
    • Lennerz V, Fatho M, Gentilini C, et al. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci USA. 2005;102(44):16013-16018.
    • (2005) Proc Natl Acad Sci USA , vol.102 , Issue.44 , pp. 16013-16018
    • Lennerz, V.1    Fatho, M.2    Gentilini, C.3
  • 124
    • 81255157774 scopus 로고    scopus 로고
    • Machine learning competition in immunology - Prediction of HLA class I binding peptides
    • Zhang GL, Ansari HR, Bradley P, et al. Machine learning competition in immunology - Prediction of HLA class I binding peptides. J Immunol Methods. 2011;374(1-2):1-4.
    • (2011) J Immunol Methods , vol.374 , Issue.1-2 , pp. 1-4
    • Zhang, G.L.1    Ansari, H.R.2    Bradley, P.3
  • 125
    • 84857725402 scopus 로고    scopus 로고
    • Exploiting the mutanome for tumor vaccination
    • Castle JC, Kreiter S, Diekmann J, et al. Exploiting the mutanome for tumor vaccination. Cancer Res. 2012;72(5):1081-1091.
    • (2012) Cancer Res , vol.72 , Issue.5 , pp. 1081-1091
    • Castle, J.C.1    Kreiter, S.2    Diekmann, J.3
  • 126
    • 0142089462 scopus 로고    scopus 로고
    • Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report
    • Liau LM, Black KL, Martin NA, et al. Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report. Neurosurg Focus. 2000;9(6):e8.
    • (2000) Neurosurg Focus , vol.9 , Issue.6 , pp. e8
    • Liau, L.M.1    Black, K.L.2    Martin, N.A.3
  • 127
    • 23044479028 scopus 로고    scopus 로고
    • Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment
    • Liau LM, Prins RM, Kiertscher SM, et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res. 2005;11(15):5515-5525.
    • (2005) Clin Cancer Res. , vol.11 , Issue.15 , pp. 5515-5525
    • Liau, L.M.1    Prins, R.M.2    Kiertscher, S.M.3
  • 128
    • 49649113879 scopus 로고    scopus 로고
    • Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme
    • De Vleeschouwer S, Fieuws S, Rutkowski S, et al. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res. 2008;14(10):3098-3104.
    • (2008) Clin Cancer Res. , vol.14 , Issue.10 , pp. 3098-3104
    • De Vleeschouwer, S.1    Fieuws, S.2    Rutkowski, S.3
  • 129
    • 11144356171 scopus 로고    scopus 로고
    • Transient local response and persistent tumor control in a child with recurrent malignant glioma: Treatment with combination therapy including dendritic cell therapy. Case report
    • De Vleeschouwer S, Van Calenbergh F, Demaerel P, et al. Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. Case report. J Neurosurg. 2004;100(5 Suppl Pediatrics):492-497.
    • (2004) J Neurosurg , vol.100 , Issue.5 , pp. 492-497
    • De Vleeschouwer, S.1    Van Calenbergh, F.2    Demaerel, P.3
  • 130
    • 9144247794 scopus 로고    scopus 로고
    • Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study
    • Rutkowski S, De Vleeschouwer S, Kaempgen E, et al. Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. Br J Cancer. 2004;91(9):1656-1662.
    • (2004) Br J Cancer , vol.91 , Issue.9 , pp. 1656-1662
    • Rutkowski, S.1    De Vleeschouwer, S.2    Kaempgen, E.3
  • 131
    • 20344372430 scopus 로고    scopus 로고
    • Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: Results of a clinical phase I/II trial
    • Yamanaka R, Homma J, Yajima N, et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res. 2005;11:4160-4167.
    • (2005) Clin Cancer Res. , vol.11 , pp. 4160-4167
    • Yamanaka, R.1    Homma, J.2    Yajima, N.3
  • 132
    • 79955591522 scopus 로고    scopus 로고
    • Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy
    • Fadul CE, Fisher JL, Hampton TH, et al. Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. J Immunother. 2011;34(4):382-389.
    • (2011) J Immunother , vol.34 , Issue.4 , pp. 382-389
    • Fadul, C.E.1    Fisher, J.L.2    Hampton, T.H.3
  • 133
    • 79952711945 scopus 로고    scopus 로고
    • Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy
    • Prins RM, Soto H, Konkankit V, et al. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res. 2011;17(6):1603-1615.
    • (2011) Clin Cancer Res. , vol.17 , Issue.6 , pp. 1603-1615
    • Prins, R.M.1    Soto, H.2    Konkankit, V.3
  • 134
    • 48649096955 scopus 로고    scopus 로고
    • Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients
    • Wheeler CJ, Black KL, Liu G, et al. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res. 2008;68(14):5955-5964.
    • (2008) Cancer Res. , vol.68 , Issue.14 , pp. 5955-5964
    • Wheeler, C.J.1    Black, K.L.2    Liu, G.3
  • 135
    • 77956061272 scopus 로고    scopus 로고
    • Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: A pilot study
    • Ardon H, Van Gool S, Lopes IS, et al. Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study. J Neurooncol. 2010;99(2):261-272.
    • (2010) J Neurooncol. , vol.99 , Issue.2 , pp. 261-272
    • Ardon, H.1    Van Gool, S.2    Lopes, I.S.3
  • 136
    • 84870985481 scopus 로고    scopus 로고
    • Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: Results of the HGG-2006 phase I/II trial
    • Ardon H, Van Gool SW, Verschuere T, et al. Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial. Cancer Immunol Immunother. 2012;61:2033-2044.
    • (2012) Cancer Immunol Immunother , vol.61 , pp. 2033-2044
    • Ardon, H.1    Van Gool, S.W.2    Verschuere, T.3
  • 137
    • 0033957941 scopus 로고    scopus 로고
    • Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma
    • Heimberger AB, Crotty LE, Archer GE, et al. Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. J Neuroimmunol. 2000;103(1):16-25.
    • (2000) J Neuroimmunol. , vol.103 , Issue.1 , pp. 16-25
    • Heimberger, A.B.1    Crotty, L.E.2    Archer, G.E.3
  • 138
    • 0033007570 scopus 로고    scopus 로고
    • Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens
    • Liau LM, Black KL, Prins RM, et al. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg. 1999;90(6):1115-1124.
    • (1999) J Neurosurg , vol.90 , Issue.6 , pp. 1115-1124
    • Liau, L.M.1    Black, K.L.2    Prins, R.M.3
  • 139
    • 78449298442 scopus 로고    scopus 로고
    • Cancer stem cells in the central nervous system - A critical review
    • Prestegarden L, Enger PO. Cancer stem cells in the central nervous system - a critical review. Cancer Res. 2010;70(21):8255-8258.
    • (2010) Cancer Res. , vol.70 , Issue.21 , pp. 8255-8258
    • Prestegarden, L.1    Enger, P.O.2
  • 140
    • 46449115281 scopus 로고    scopus 로고
    • Stemcell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma
    • Murat A, Migliavacca E, Gorlia T, et al. Stemcell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol. 2008;26(18):3015-3024.
    • (2008) J Clin Oncol. , vol.26 , Issue.18 , pp. 3015-3024
    • Murat, A.1    Migliavacca, E.2    Gorlia, T.3
  • 141
    • 33845317573 scopus 로고    scopus 로고
    • Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
    • Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444(7120):756-760.
    • (2006) Nature , vol.444 , Issue.7120 , pp. 756-760
    • Bao, S.1    Wu, Q.2    McLendon, R.E.3
  • 142
    • 78049270536 scopus 로고    scopus 로고
    • Glioma cancer stem cells induce immunosuppressive macrophages/microglia
    • Wu A, Wei J, Kong LY, et al. Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro-oncol. 2010;12(11):1113-1125.
    • (2010) Neuro-oncol. , vol.12 , Issue.11 , pp. 1113-1125
    • Wu, A.1    Wei, J.2    Kong, L.Y.3
  • 143
    • 76049114698 scopus 로고    scopus 로고
    • Immunobiological characterization of cancer stem cells isolated from glioblastoma patients
    • Di Tomaso T, Mazzoleni S, Wang E, et al. Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin Cancer Res. 2010;16(3):800-813.
    • (2010) Clin Cancer Res. , vol.16 , Issue.3 , pp. 800-813
    • Di Tomaso, T.1    Mazzoleni, S.2    Wang, E.3
  • 144
    • 69249149701 scopus 로고    scopus 로고
    • Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens
    • Xu Q, Liu G, Yuan X, et al. Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens. Stem cells. 2009;27(8):1734-1740.
    • (2009) Stem Cells , vol.27 , Issue.8 , pp. 1734-1740
    • Xu, Q.1    Liu, G.2    Yuan, X.3
  • 145
    • 33751297619 scopus 로고    scopus 로고
    • Neurospheres Enriched in Cancer Stem-Like Cells Are Highly Effective in Eliciting a Dendritic Cell-Mediated Immune Response against Malignant Gliomas
    • Pellegatta S, Poliani PL, Corno D, et al. Neurospheres Enriched in Cancer Stem-Like Cells Are Highly Effective in Eliciting a Dendritic Cell-Mediated Immune Response against Malignant Gliomas. Cancer Res. 2006;66(21):10247-10252.
    • (2006) Cancer Res. , vol.66 , Issue.21 , pp. 10247-10252
    • Pellegatta, S.1    Poliani, P.L.2    Corno, D.3
  • 146
    • 0032695108 scopus 로고    scopus 로고
    • Natural adjuvants: Endogenous activators of dendritic cells
    • Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat Med. 1999;5(11):1249-1255.
    • (1999) Nat Med. , vol.5 , Issue.11 , pp. 1249-1255
    • Gallucci, S.1    Lolkema, M.2    Matzinger, P.3
  • 147
    • 84893073441 scopus 로고    scopus 로고
    • Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: A phase II, single-arm trial
    • Bloch O, Crane CA, Fuks Y, et al. Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. Neuro Oncol. 2014;16(2):274-279.
    • (2014) Neuro Oncol. , vol.16 , Issue.2 , pp. 274-279
    • Bloch, O.1    Crane, C.A.2    Fuks, Y.3
  • 148
    • 84871951211 scopus 로고    scopus 로고
    • Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein
    • Crane CA, Han SJ, Ahn B, et al. Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein. Clin Cancer Res. 2013;19(1):205-214.
    • (2013) Clin Cancer Res. , vol.19 , Issue.1 , pp. 205-214
    • Crane, C.A.1    Han, S.J.2    Ahn, B.3
  • 150
    • 34248204110 scopus 로고    scopus 로고
    • DC-based cancer vaccines
    • Gilboa E. DC-based cancer vaccines. J Clin Invest. 2007;117(5):1195-1203.
    • (2007) J Clin Invest. , vol.117 , Issue.5 , pp. 1195-1203
    • Gilboa, E.1
  • 151
    • 84859709790 scopus 로고    scopus 로고
    • New developments in vaccine research-unveiling the secret of vaccine adjuvants
    • de Veer M, Meeusen E. New developments in vaccine research-unveiling the secret of vaccine adjuvants. Discov Med. 2011;12(64):195-204.
    • (2011) Discov Med. , vol.12 , Issue.64 , pp. 195-204
    • De Veer, M.1    Meeusen, E.2
  • 152
    • 79955859969 scopus 로고    scopus 로고
    • Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines
    • Chiang CL, Kandalaft LE, Coukos G. Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines. Int Rev Immunol. 2011;30(2-3):150-182.
    • (2011) Int Rev Immunol. , vol.30 , Issue.2-3 , pp. 150-182
    • Chiang, C.L.1    Kandalaft, L.E.2    Coukos, G.3
  • 153
    • 79955083788 scopus 로고    scopus 로고
    • Trends in vaccine adjuvants
    • Schijns VE, Lavelle EC. Trends in vaccine adjuvants. Exp Rev Vaccines. 2011;10(4):539-550.
    • (2011) Exp Rev Vaccines , vol.10 , Issue.4 , pp. 539-550
    • Schijns, V.E.1    Lavelle, E.C.2
  • 154
    • 84858780815 scopus 로고    scopus 로고
    • Cancer immunotherapy via dendritic cells
    • Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012;12(4):265-277.
    • (2012) Nat Rev Cancer , vol.12 , Issue.4 , pp. 265-277
    • Palucka, K.1    Banchereau, J.2
  • 155
    • 17644370329 scopus 로고    scopus 로고
    • Cell biology of antigen processing in vitro and in vivo
    • Trombetta ES, Mellman I. Cell biology of antigen processing in vitro and in vivo. Ann Rev Immunol. 2005;23:975-1028.
    • (2005) Ann Rev Immunol. , vol.23 , pp. 975-1028
    • Trombetta, E.S.1    Mellman, I.2
  • 156
    • 69549103141 scopus 로고    scopus 로고
    • Feedback control of regulatory T cell homeostasis by dendritic cells in vivo
    • Darrasse-Jeze G, Deroubaix S, Mouquet H, et al. Feedback control of regulatory T cell homeostasis by dendritic cells in vivo. J Exp Med. 2009;206(9):1853-1862.
    • (2009) J Exp Med. , vol.206 , Issue.9 , pp. 1853-1862
    • Darrasse-Jeze, G.1    Deroubaix, S.2    Mouquet, H.3
  • 157
    • 77957982756 scopus 로고    scopus 로고
    • Toll-like receptor agonists: Are they good adjuvants?
    • Gnjatic S, Sawhney NB, Bhardwaj N. Toll-like receptor agonists: are they good adjuvants?. Cancer J. 2010;16(4):382-391.
    • (2010) Cancer J. , vol.16 , Issue.4 , pp. 382-391
    • Gnjatic, S.1    Sawhney, N.B.2    Bhardwaj, N.3
  • 158
    • 84863000097 scopus 로고    scopus 로고
    • Immunotherapeutic approach with oligodeoxynucleotides containing CpG motifs (CpG-ODN) in malignant glioma
    • Ursu R, Carpentier AF. Immunotherapeutic approach with oligodeoxynucleotides containing CpG motifs (CpG-ODN) in malignant glioma. Adv Exp Med Biol. 2012;746:95-108.
    • (2012) Adv Exp Med Biol. , vol.746 , pp. 95-108
    • Ursu, R.1    Carpentier, A.F.2
  • 159
    • 29644446061 scopus 로고    scopus 로고
    • The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: Relation to central nervous system antitumor immunity
    • Prins RM, Craft N, Bruhn KW, et al. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J Immunol. 2006;176(1):157-164.
    • (2006) J Immunol. , vol.176 , Issue.1 , pp. 157-164
    • Prins, R.M.1    Craft, N.2    Bruhn, K.W.3
  • 160
  • 161
    • 0034060821 scopus 로고    scopus 로고
    • Keyhole limpet haemocyanin in experimental bladder cancer: Literature review and own results
    • Linn JF, Black P, Derksen K, et al. Keyhole limpet haemocyanin in experimental bladder cancer: literature review and own results. Eur Urol. 2000;37(Suppl 3):34-40.
    • (2000) Eur Urol. , vol.37 , pp. 34-40
    • Linn, J.F.1    Black, P.2    Derksen, K.3
  • 162
    • 84860798836 scopus 로고    scopus 로고
    • The regulation of the development and function of dendritic cell subsets by GM-CSF: More than a hematopoietic growth factor
    • Zhan Y, Xu Y, Lew AM. The regulation of the development and function of dendritic cell subsets by GM-CSF: more than a hematopoietic growth factor. Mol Immunol. 2012;52(1):30-37.
    • (2012) Mol Immunol. , vol.52 , Issue.1 , pp. 30-37
    • Zhan, Y.1    Xu, Y.2    Lew, A.M.3
  • 163
    • 0037441842 scopus 로고    scopus 로고
    • Vaccination with irradiated autologous tumor cells engineered to secrete granulocytemacrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma
    • Salgia R, Lynch T, Skarin A, et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocytemacrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol. 2003;21(4):624-630.
    • (2003) J Clin Oncol. , vol.21 , Issue.4 , pp. 624-630
    • Salgia, R.1    Lynch, T.2    Skarin, A.3
  • 164
    • 0141576738 scopus 로고    scopus 로고
    • Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocytemacrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma
    • Soiffer R, Hodi FS, Haluska F, et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocytemacrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol. 2003;21(17):3343-3350.
    • (2003) J Clin Oncol. , vol.21 , Issue.17 , pp. 3343-3350
    • Soiffer, R.1    Hodi, F.S.2    Haluska, F.3
  • 165
    • 22144497779 scopus 로고    scopus 로고
    • Vaccines in cancer: GVAX, a GM-CSF gene vaccine
    • Nemunaitis J. Vaccines in cancer: GVAX, a GM-CSF gene vaccine. Exp Rev Vaccines. 2005;4(3):259-274.
    • (2005) Exp Rev Vaccines , vol.4 , Issue.3 , pp. 259-274
    • Nemunaitis, J.1
  • 166
    • 33847258205 scopus 로고    scopus 로고
    • Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients
    • Parmiani G, Castelli C, Pilla L, et al. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol. 2007;18(2):226-232.
    • (2007) Ann Oncol. , vol.18 , Issue.2 , pp. 226-232
    • Parmiani, G.1    Castelli, C.2    Pilla, L.3
  • 167
    • 77952125524 scopus 로고    scopus 로고
    • Use of GM-CSF as an adjuvant with cancer vaccines: Beneficial or detrimental?
    • Clive KS, Tyler JA, Clifton GT, et al. Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental?. Exp Rev Vaccines. 2010;9(5):519-525.
    • (2010) Exp Rev Vaccines , vol.9 , Issue.5 , pp. 519-525
    • Clive, K.S.1    Tyler, J.A.2    Clifton, G.T.3
  • 168
    • 34447121852 scopus 로고    scopus 로고
    • MFG-E8-mediated uptake of apoptotic cells by APCs links the pro- and antiinflammatory activities of GM-CSF
    • Jinushi M, Nakazaki Y, Dougan M, et al. MFG-E8-mediated uptake of apoptotic cells by APCs links the pro- and antiinflammatory activities of GM-CSF. J Clin Invest. 2007;117(7):1902-1913.
    • (2007) J Clin Invest. , vol.117 , Issue.7 , pp. 1902-1913
    • Jinushi, M.1    Nakazaki, Y.2    Dougan, M.3
  • 169
    • 84872184215 scopus 로고    scopus 로고
    • Vaccine injection site matters: Qualitative and quantitative defects in CD8 T cells primed as a function of proximity to the tumor in a murine glioma model
    • Ohlfest JR, Andersen BM, Litterman AJ, et al. Vaccine injection site matters: qualitative and quantitative defects in CD8 T cells primed as a function of proximity to the tumor in a murine glioma model. J Immunol. 2013;190(2):613-620.
    • (2013) J Immunol. , vol.190 , Issue.2 , pp. 613-620
    • Ohlfest, J.R.1    Andersen, B.M.2    Litterman, A.J.3
  • 170
    • 0142179258 scopus 로고    scopus 로고
    • Thymic CD8+ T-cell production strongly influences tumor antigen recognition and agedependent glioma mortality
    • Wheeler CJ, Black KL, Liu G, et al. Thymic CD8+ T-cell production strongly influences tumor antigen recognition and agedependent glioma mortality. J Immunol. 2003;171:4927-4933.
    • (2003) J Immunol. , vol.171 , pp. 4927-4933
    • Wheeler, C.J.1    Black, K.L.2    Liu, G.3
  • 171
    • 84870982871 scopus 로고    scopus 로고
    • Stratification according to HGG-IMMUNO RPA model predicts outcome in a large group of patients with relapsed malignant glioma treated by adjuvant postoperative dendritic cell vaccination
    • De Vleeschouwer S, Ardon H, Van Calenbergh F, et al. Stratification according to HGG-IMMUNO RPA model predicts outcome in a large group of patients with relapsed malignant glioma treated by adjuvant postoperative dendritic cell vaccination. Cancer Immunol Immunother. 2012;61:2105-2112.
    • (2012) Cancer Immunol Immunother , vol.61 , pp. 2105-2112
    • De Vleeschouwer, S.1    Ardon, H.2    Van Calenbergh, F.3
  • 172
    • 84886943535 scopus 로고    scopus 로고
    • The natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysates
    • Pellegatta S, Eoli M, Frigerio S, et al. The natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysates. Oncoimmunology. 2013;2(3):e23401.
    • (2013) Oncoimmunology , vol.2 , Issue.3 , pp. e23401
    • Pellegatta, S.1    Eoli, M.2    Frigerio, S.3
  • 173
    • 84857547272 scopus 로고    scopus 로고
    • A pilot study of IL-2Ralpha blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma
    • Sampson JH, Schmittling RJ, Archer GE, et al. A pilot study of IL-2Ralpha blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma. PloS One. 2012;7(2):e31046.
    • (2012) PloS One , vol.7 , Issue.2 , pp. e31046
    • Sampson, J.H.1    Schmittling, R.J.2    Archer, G.E.3
  • 174
    • 79959772576 scopus 로고    scopus 로고
    • Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
    • Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. New Engl J Med. 2011;364(26):2517-2526.
    • (2011) New Engl J Med. , vol.364 , Issue.26 , pp. 2517-2526
    • Robert, C.1    Thomas, L.2    Bondarenko, I.3
  • 175
    • 65349119978 scopus 로고    scopus 로고
    • CD28 and CTLA-4 coreceptor expression and signal transduction
    • Rudd CE, Taylor A, Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev. 2009;229(1):12-26.
    • (2009) Immunol Rev. , vol.229 , Issue.1 , pp. 12-26
    • Rudd, C.E.1    Taylor, A.2    Schneider, H.3
  • 176
    • 0028675006 scopus 로고
    • Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors.[erratum appears in Immunity 1995 Feb;2 (2): Following 203]
    • Linsley PS, Greene JL, Brady W, et al. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors.[erratum appears in Immunity 1995 Feb;2 (2) :following 203]. Immunity. 1994;1(9):793-801.
    • (1994) Immunity , vol.1 , Issue.9 , pp. 793-801
    • Linsley, P.S.1    Greene, J.L.2    Brady, W.3
  • 177
    • 53749094183 scopus 로고    scopus 로고
    • CTLA-4 control over Foxp3+ regulatory T cell function
    • Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science. 2008;322(5899):271-275.
    • (2008) Science , vol.322 , Issue.5899 , pp. 271-275
    • Wing, K.1    Onishi, Y.2    Prieto-Martin, P.3
  • 178
    • 68149155982 scopus 로고    scopus 로고
    • Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies
    • Peggs KS, Quezada SA, Chambers CA, et al. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med. 2009;206(8):1717-1725.
    • (2009) J Exp Med. , vol.206 , Issue.8 , pp. 1717-1725
    • Peggs, K.S.1    Quezada, S.A.2    Chambers, C.A.3
  • 179
    • 61349139964 scopus 로고    scopus 로고
    • Regulation of arginase I activity and expression by both PD-1 and CTLA-4 on the myeloid-derived suppressor cells
    • Liu Y, Yu Y, Yang S, et al. Regulation of arginase I activity and expression by both PD-1 and CTLA-4 on the myeloid-derived suppressor cells. Cancer Immunol Immunother. 2009;58(5):687-697.
    • (2009) Cancer Immunol Immunother , vol.58 , Issue.5 , pp. 687-697
    • Liu, Y.1    Yu, Y.2    Yang, S.3
  • 180
    • 0028791059 scopus 로고
    • Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4
    • Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science. 1995;270(5238):985-988.
    • (1995) Science , vol.270 , Issue.5238 , pp. 985-988
    • Waterhouse, P.1    Penninger, J.M.2    Timms, E.3
  • 181
    • 38449115210 scopus 로고    scopus 로고
    • PD-1 regulates self-reactive CD8+ T cell responses to antigen in lymph nodes and tissues
    • Keir ME, Freeman GJ, Sharpe AH. PD-1 regulates self-reactive CD8+ T cell responses to antigen in lymph nodes and tissues. J Immunol. 2007;179(8):5064-5070.
    • (2007) J Immunol. , vol.179 , Issue.8 , pp. 5064-5070
    • Keir, M.E.1    Freeman, G.J.2    Sharpe, A.H.3
  • 182
    • 0026700235 scopus 로고
    • Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death
    • Ishida Y, Agata Y, Shibahara K, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11(11):3887-3895.
    • (1992) EMBO J. , vol.11 , Issue.11 , pp. 3887-3895
    • Ishida, Y.1    Agata, Y.2    Shibahara, K.3
  • 183
    • 32544459770 scopus 로고    scopus 로고
    • Restoring function in exhausted CD8T cells during chronic viral infection
    • Barber DL, Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8T cells during chronic viral infection. Nature. 2006;439(7077):682-687.
    • (2006) Nature , vol.439 , Issue.7077 , pp. 682-687
    • Barber, D.L.1    Wherry, E.J.2    Masopust, D.3
  • 184
    • 0034596948 scopus 로고    scopus 로고
    • Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
    • Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027-1034.
    • (2000) J Exp Med. , vol.192 , Issue.7 , pp. 1027-1034
    • Freeman, G.J.1    Long, A.J.2    Iwai, Y.3
  • 185
    • 62249172189 scopus 로고    scopus 로고
    • Enhancing SIV-specific immunity in vivo by PD-1 blockade
    • Velu V, Titanji K, Zhu B, et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature. 2009;458(7235):206-210.
    • (2009) Nature , vol.458 , Issue.7235 , pp. 206-210
    • Velu, V.1    Titanji, K.2    Zhu, B.3
  • 186
    • 80051698136 scopus 로고    scopus 로고
    • IL-18 induces PD-1-dependent immunosuppression in cancer
    • Terme M, Ullrich E, Aymeric L, et al. IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res. 2011;71(16):5393-5399.
    • (2011) Cancer Res. , vol.71 , Issue.16 , pp. 5393-5399
    • Terme, M.1    Ullrich, E.2    Aymeric, L.3
  • 187
    • 44349150012 scopus 로고    scopus 로고
    • Inhibitory B7-family molecules in the tumour microenvironment
    • Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008;8(6):467-477.
    • (2008) Nat Rev Immunol. , vol.8 , Issue.6 , pp. 467-477
    • Zou, W.1    Chen, L.2
  • 188
    • 84859128199 scopus 로고    scopus 로고
    • Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape
    • Taube JM, Anders RA, Young GD, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4(127):127ra37.
    • (2012) Sci Transl Med. , vol.4 , Issue.127 , pp. 127ra37
    • Taube, J.M.1    Anders, R.A.2    Young, G.D.3
  • 189
    • 33846118474 scopus 로고    scopus 로고
    • Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
    • Parsa AT, Waldron JS, Panner A, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med. 2007;13(1):84-88.
    • (2007) Nat Med. , vol.13 , Issue.1 , pp. 84-88
    • Parsa, A.T.1    Waldron, J.S.2    Panner, A.3
  • 190
    • 73249125835 scopus 로고    scopus 로고
    • B7-H1 is correlated with malignancy-grade gliomas but is not expressed exclusively on tumor stem-like cells
    • Yao Y, Tao R, Wang X, et al. B7-H1 is correlated with malignancy-grade gliomas but is not expressed exclusively on tumor stem-like cells. Neuro Oncol. 2009;11(6):757-766.
    • (2009) Neuro Oncol. , vol.11 , Issue.6 , pp. 757-766
    • Yao, Y.1    Tao, R.2    Wang, X.3
  • 191
    • 0242442492 scopus 로고    scopus 로고
    • Expression of the B7-related molecule B7-H1 by glioma cells: A potential mechanism of immune paralysis
    • Wintterle S, Schreiner B, Mitsdoerffer M, et al. Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res. 2003;63(21):7462-7467.
    • (2003) Cancer Res. , vol.63 , Issue.21 , pp. 7462-7467
    • Wintterle, S.1    Schreiner, B.2    Mitsdoerffer, M.3
  • 192
    • 77955665451 scopus 로고    scopus 로고
    • Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2, 3-dioxygenase (IDO) on tumour-specific T cell functions
    • Avril T, Saikali S, Vauleon E, et al. Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2, 3-dioxygenase (IDO) on tumour-specific T cell functions. J Neuroimmunol. 2010;225(1-2):22-33.
    • (2010) J Neuroimmunol. , vol.225 , Issue.1-2 , pp. 22-33
    • Avril, T.1    Saikali, S.2    Vauleon, E.3
  • 193
    • 22544486023 scopus 로고    scopus 로고
    • B7-homolog 1 expression by human glioma: A new mechanism of immune evasion
    • Wilmotte R, Burkhardt K, Kindler V, et al. B7-homolog 1 expression by human glioma: a new mechanism of immune evasion. Neuroreport. 2005;16(10):1081-1085.
    • (2005) Neuroreport , vol.16 , Issue.10 , pp. 1081-1085
    • Wilmotte, R.1    Burkhardt, K.2    Kindler, V.3
  • 194
    • 68949085209 scopus 로고    scopus 로고
    • Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors
    • Jacobs JF, Idema AJ, Bol KF, et al. Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. Neuro Oncol. 2009;11(4):394-402.
    • (2009) Neuro Oncol. , vol.11 , Issue.4 , pp. 394-402
    • Jacobs, J.F.1    Idema, A.J.2    Bol, K.F.3
  • 195
    • 34247502076 scopus 로고    scopus 로고
    • Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function
    • Fecci PE, Ochiai H, Mitchell DA, et al. Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res. 2007;13(7):2158-2167.
    • (2007) Clin Cancer Res. , vol.13 , Issue.7 , pp. 2158-2167
    • Fecci, P.E.1    Ochiai, H.2    Mitchell, D.A.3
  • 196
    • 84890846323 scopus 로고    scopus 로고
    • Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell-mediated glioma rejection
    • Vom Berg J, Vrohlings M, Haller S, et al. Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell-mediated glioma rejection. J Exp Med. 2013;210(13):2803-2811.
    • (2013) J Exp Med. , vol.210 , Issue.13 , pp. 2803-2811
    • Vom Berg, J.1    Vrohlings, M.2    Haller, S.3
  • 197
    • 84877581852 scopus 로고    scopus 로고
    • Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas
    • Zeng J, See AP, Phallen J, et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys. 2013;86(2):343-349.
    • (2013) Int J Radiat Oncol Biol Phys. , vol.86 , Issue.2 , pp. 343-349
    • Zeng, J.1    See, A.P.2    Phallen, J.3
  • 198
    • 84865553349 scopus 로고    scopus 로고
    • How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma
    • Wolchok J. How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma. Ann Oncol. 2012;23(Suppl 8):viii15-21.
    • (2012) Ann Oncol. , vol.23 , pp. viii15-viii21
    • Wolchok, J.1
  • 199
    • 84859393995 scopus 로고    scopus 로고
    • CTLA-4 blockade with ipilimumab: Long-term follow-up of 177 patients with metastatic melanoma
    • Prieto PA, Yang JC, Sherry RM, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res. 2012;18(7):2039-2047.
    • (2012) Clin Cancer Res. , vol.18 , Issue.7 , pp. 2039-2047
    • Prieto, P.A.1    Yang, J.C.2    Sherry, R.M.3
  • 200
    • 84874605864 scopus 로고    scopus 로고
    • Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
    • Ribas A, Kefford R, Marshall MA, et al. Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma. J Clin Oncol. 2013;31:616-622.
    • (2013) J Clin Oncol. , vol.31 , pp. 616-622
    • Ribas, A.1    Kefford, R.2    Marshall, M.A.3
  • 201
    • 84863911486 scopus 로고    scopus 로고
    • Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: Results from a randomized, double-blind, multicenter phase II study
    • Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol. 2012;30(17):2046-2054.
    • (2012) J Clin Oncol. , vol.30 , Issue.17 , pp. 2046-2054
    • Lynch, T.J.1    Bondarenko, I.2    Luft, A.3
  • 202
    • 84860455345 scopus 로고    scopus 로고
    • Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: A phase 1 dose-escalation trial
    • Madan RA, Mohebtash M, Arlen PM, et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13(5):501-508.
    • (2012) Lancet Oncol. , vol.13 , Issue.5 , pp. 501-508
    • Madan, R.A.1    Mohebtash, M.2    Arlen, P.M.3
  • 203
    • 84862754605 scopus 로고    scopus 로고
    • Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer
    • McNeel DG, Smith HA, Eickhoff JC, et al. Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer. Cancer Immunol Immunother. 2012;61(7):1137-1147.
    • (2012) Cancer Immunol Immunother. , vol.61 , Issue.7 , pp. 1137-1147
    • McNeel, D.G.1    Smith, H.A.2    Eickhoff, J.C.3
  • 204
    • 77954230122 scopus 로고    scopus 로고
    • Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells
    • Vonderheide RH, LoRusso PM, Khalil M, et al. Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. Clin Cancer Res. 2012;16(13):3485-3494.
    • (2012) Clin Cancer Res. , vol.16 , Issue.13 , pp. 3485-3494
    • Vonderheide, R.H.1    LoRusso, P.M.2    Khalil, M.3
  • 205
    • 77955292303 scopus 로고    scopus 로고
    • Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer
    • Chung KY, Gore I, Fong L, et al. Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. J Clin Oncol. 2010;28(21):3485-3490.
    • (2010) J Clin Oncol. , vol.28 , Issue.21 , pp. 3485-3490
    • Chung, K.Y.1    Gore, I.2    Fong, L.3
  • 206
    • 37349072460 scopus 로고    scopus 로고
    • Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis
    • Yang JC, Hughes M, Kammula U, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007;30(8):825-830.
    • (2007) J Immunother. , vol.30 , Issue.8 , pp. 825-830
    • Yang, J.C.1    Hughes, M.2    Kammula, U.3
  • 207
    • 77958050577 scopus 로고    scopus 로고
    • Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma
    • Royal RE, Levy C, Turner K, et al. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 2010;33(8):828-833.
    • (2010) J Immunother. , vol.33 , Issue.8 , pp. 828-833
    • Royal, R.E.1    Levy, C.2    Turner, K.3
  • 208
    • 84884703526 scopus 로고    scopus 로고
    • Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: An open-label, single-arm, phase 2 trial
    • Calabro L, Morra A, Fonsatti E, et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2013;14(11):1104-1111.
    • (2013) Lancet Oncol. , vol.14 , Issue.11 , pp. 1104-1111
    • Calabro, L.1    Morra, A.2    Fonsatti, E.3
  • 209
    • 84879759020 scopus 로고    scopus 로고
    • Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma
    • Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369(2):134-144.
    • (2013) N Engl J Med. , vol.369 , Issue.2 , pp. 134-144
    • Hamid, O.1    Robert, C.2    Daud, A.3
  • 210
    • 84864052441 scopus 로고    scopus 로고
    • Management of immune-related adverse events and kinetics of response with ipilimumab
    • Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30(21):2691-2697.
    • (2012) J Clin Oncol. , vol.30 , Issue.21 , pp. 2691-2697
    • Weber, J.S.1    Kahler, K.C.2    Hauschild, A.3
  • 211
    • 84886443514 scopus 로고    scopus 로고
    • CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients
    • Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients. Clin Cancer Res. 2013;19(19):5300-5309.
    • (2013) Clin Cancer Res. , vol.19 , Issue.19 , pp. 5300-5309
    • Ott, P.A.1    Hodi, F.S.2    Robert, C.3
  • 212
    • 84876678621 scopus 로고    scopus 로고
    • Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: Detailed safety analysis from a phase 3 trial in patients with advanced melanoma
    • Weber JS, Dummer R, de Pril V, et al. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer. 2013;119(9):1675-1682.
    • (2013) Cancer. , vol.119 , Issue.9 , pp. 1675-1682
    • Weber, J.S.1    Dummer, R.2    De Pril, V.3
  • 213
    • 84881186333 scopus 로고    scopus 로고
    • Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma
    • Feng Y, Roy A, Masson E, et al. Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma. Clin Cancer Res. 2013;19(14):3977-3986.
    • (2013) Clin Cancer Res. , vol.19 , Issue.14 , pp. 3977-3986
    • Feng, Y.1    Roy, A.2    Masson, E.3
  • 214
    • 84860446616 scopus 로고    scopus 로고
    • Ipilimumab in patients with melanoma and brain metastases: An open-label, phase 2 trial
    • Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012;13(5):459-465.
    • (2012) Lancet Oncol. , vol.13 , Issue.5 , pp. 459-465
    • Margolin, K.1    Ernstoff, M.S.2    Hamid, O.3
  • 215
    • 84877043331 scopus 로고    scopus 로고
    • Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery
    • Mathew M, Tam M, Ott PA, et al. Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. Melanoma Res. 2013;23(3):191-195.
    • (2013) Melanoma Res. , vol.23 , Issue.3 , pp. 191-195
    • Mathew, M.1    Tam, M.2    Ott, P.A.3
  • 216
    • 84904216679 scopus 로고    scopus 로고
    • Ipilimumab and radiation therapy for melanoma brain metastases
    • Silk AW, Bassetti MF, West BT, et al. Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med. 2013;2(6):899-906.
    • (2013) Cancer Med. , vol.2 , Issue.6 , pp. 899-906
    • Silk, A.W.1    Bassetti, M.F.2    West, B.T.3
  • 217
    • 51149116051 scopus 로고    scopus 로고
    • CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nature clinical practice
    • Hodi FS, Oble DA, Drappatz J, et al. CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nature clinical practice. Oncology. 2008;5(9):557-561.
    • (2008) Oncology , vol.5 , Issue.9 , pp. 557-561
    • Hodi, F.S.1    Oble, D.A.2    Drappatz, J.3
  • 218
    • 84879112954 scopus 로고    scopus 로고
    • Profound impairment of adaptive immune responses by alkylating chemotherapy
    • Litterman AJ, Zellmer DM, Grinnen KL, et al. Profound impairment of adaptive immune responses by alkylating chemotherapy. J Immunol. 2013;190(12):6259-6268.
    • (2013) J Immunol. , vol.190 , Issue.12 , pp. 6259-6268
    • Litterman, A.J.1    Zellmer, D.M.2    Grinnen, K.L.3
  • 219
    • 84912052604 scopus 로고    scopus 로고
    • The association between severe treatment-related lymphopenia and progression free survival in patients with newly diagnosed squamous cell head and neck cancer
    • Epub ahead of print
    • Campian J, Sarai G, Ye X, et al. The association between severe treatment-related lymphopenia and progression free survival in patients with newly diagnosed squamous cell head and neck cancer. Head Neck. 2013. doi: 10.1002/hed.23535. [Epub ahead of print].
    • (2013) Head Neck.
    • Campian, J.1    Sarai, G.2    Ye, X.3
  • 220
    • 84875048243 scopus 로고    scopus 로고
    • Treatment-related lymphopenia in patients with stage III non-small-cell lung cancer
    • Campian JL, Ye X, Brock M, et al. Treatment-related lymphopenia in patients with stage III non-small-cell lung cancer. Cancer Invest. 2013;31(3):183-188.
    • (2013) Cancer Invest. , vol.31 , Issue.3 , pp. 183-188
    • Campian, J.L.1    Ye, X.2    Brock, M.3
  • 221
    • 84970918518 scopus 로고    scopus 로고
    • The Association Between Chemoradiation-related Lymphopenia and Clinical Outcomes in Patients With Locally Advanced Pancreatic Adenocarcinoma
    • epub
    • Wild AT, Ye X, Ellsworth SG, et al. The Association Between Chemoradiation-related Lymphopenia and Clinical Outcomes in Patients With Locally Advanced Pancreatic Adenocarcinoma. Am J Clin Oncol. 2013. epub.
    • (2013) Am J Clin Oncol.
    • Wild, A.T.1    Ye, X.2    Ellsworth, S.G.3
  • 222
    • 79952390627 scopus 로고    scopus 로고
    • Immune parameters affecting the efficacy of chemotherapeutic regimens
    • Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol. 2011;8(3):151-160.
    • (2011) Nat Rev Clin Oncol. , vol.8 , Issue.3 , pp. 151-160
    • Zitvogel, L.1    Kepp, O.2    Kroemer, G.3
  • 223
    • 49249127841 scopus 로고    scopus 로고
    • Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies
    • Apetoh L, Tesniere A, Ghiringhelli F, et al. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res. 2008;68(11):4026-4030.
    • (2008) Cancer Res. , vol.68 , Issue.11 , pp. 4026-4030
    • Apetoh, L.1    Tesniere, A.2    Ghiringhelli, F.3
  • 224
    • 84875068031 scopus 로고    scopus 로고
    • Myeloablative temozolomide enhances CD8 (+) T-cell responses to vaccine and is required for efficacy against brain tumors in mice
    • Sanchez-Perez LA, Choi BD, Archer GE, et al. Myeloablative temozolomide enhances CD8 (+) T-cell responses to vaccine and is required for efficacy against brain tumors in mice. PLoS One. 2013;8(3):e59082.
    • (2013) PLoS One , vol.8 , Issue.3 , pp. e59082
    • Sanchez-Perez, L.A.1    Choi, B.D.2    Archer, G.E.3
  • 225
    • 84866920006 scopus 로고    scopus 로고
    • Post-chemotherapy T-cell recovery is a marker of improved survival in patients with advanced thoracic malignancies
    • McCoy MJ, Lake RA, van der Most RG, et al. Post-chemotherapy T-cell recovery is a marker of improved survival in patients with advanced thoracic malignancies. Br J Cancer. 2012;107(7):1107-1115.
    • (2012) Br J Cancer , vol.107 , Issue.7 , pp. 1107-1115
    • McCoy, M.J.1    Lake, R.A.2    Van Der Most, R.G.3
  • 226
    • 33847368549 scopus 로고    scopus 로고
    • Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
    • Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother. 2007;56(5):641-648.
    • (2007) Cancer Immunol Immunother , vol.56 , Issue.5 , pp. 641-648
    • Ghiringhelli, F.1    Menard, C.2    Puig, P.E.3
  • 227
    • 25144466458 scopus 로고    scopus 로고
    • Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity
    • Suzuki E, Kapoor V, Jassar AS, et al. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res. 2005;11(18):6713-6721.
    • (2005) Clin Cancer Res. , vol.11 , Issue.18 , pp. 6713-6721
    • Suzuki, E.1    Kapoor, V.2    Jassar, A.S.3
  • 228
    • 84872086179 scopus 로고    scopus 로고
    • Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth
    • Bruchard M, Mignot G, Derangere V, et al. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med. 2013;19(1):57-64.
    • (2013) Nat Med. , vol.19 , Issue.1 , pp. 57-64
    • Bruchard, M.1    Mignot, G.2    Derangere, V.3
  • 229
    • 77956911325 scopus 로고    scopus 로고
    • Chemotherapy-induced genotoxic stress promotes sensitivity to natural killer cell cytotoxicity by enabling missing-self recognition
    • Fine JH, Chen P, Mesci A, et al. Chemotherapy-induced genotoxic stress promotes sensitivity to natural killer cell cytotoxicity by enabling missing-self recognition. Cancer Res. 2010;70(18):7102-7113.
    • (2010) Cancer Res. , vol.70 , Issue.18 , pp. 7102-7113
    • Fine, J.H.1    Chen, P.2    Mesci, A.3
  • 230
    • 81155154274 scopus 로고    scopus 로고
    • Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control
    • Hong M, Puaux AL, Huang C, et al. Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control. Cancer Res. 2011;71(22):6997-7009.
    • (2011) Cancer Res. , vol.71 , Issue.22 , pp. 6997-7009
    • Hong, M.1    Puaux, A.L.2    Huang, C.3
  • 231
    • 84886944998 scopus 로고    scopus 로고
    • Exploiting the stress response to radiation to sensitize poorly immunogenic tumors to anti-CTLA-4 treatment
    • Demaria S, Pilones KA, Formenti SC, et al. Exploiting the stress response to radiation to sensitize poorly immunogenic tumors to anti-CTLA-4 treatment. Oncoimmunology. 2013;2(3):e23127.
    • (2013) Oncoimmunology , vol.2 , Issue.3 , pp. e23127
    • Demaria, S.1    Pilones, K.A.2    Formenti, S.C.3
  • 232
    • 84857815877 scopus 로고    scopus 로고
    • Immunologic correlates of the abscopal effect in a patient with melanoma
    • Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. New Engl J Med. 2012;366(10):925-931.
    • (2012) New Engl J Med. , vol.366 , Issue.10 , pp. 925-931
    • Postow, M.A.1    Callahan, M.K.2    Barker, C.A.3
  • 233
    • 84876522514 scopus 로고    scopus 로고
    • Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity
    • Lesterhuis WJ, Salmons J, Nowak AK, et al. Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity. PLoS One. 2013;8(4):e61895.
    • (2013) PLoS One , vol.8 , Issue.4 , pp. e61895
    • Lesterhuis, W.J.1    Salmons, J.2    Nowak, A.K.3
  • 234
    • 0032400862 scopus 로고    scopus 로고
    • Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo
    • Gabrilovich D, Ishida T, Oyama T, et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood. 1998;92(11):4150-4166.
    • (1998) Blood. , vol.92 , Issue.11 , pp. 4150-4166
    • Gabrilovich, D.1    Ishida, T.2    Oyama, T.3
  • 235
    • 0029842830 scopus 로고    scopus 로고
    • Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells
    • Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 1996;2(10):1096-1103.
    • (1996) Nat Med. , vol.2 , Issue.10 , pp. 1096-1103
    • Gabrilovich, D.I.1    Chen, H.L.2    Girgis, K.R.3
  • 236
    • 34047131797 scopus 로고    scopus 로고
    • Vascular endothelial growth factor and immunosuppression in cancer: Current knowledge and potential for new therapy
    • Johnson BF, Clay TM, Hobeika AC, et al. Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy. Exp Opin Biol Ther. 2007;7(4):449-460.
    • (2007) Exp Opin Biol Ther. , vol.7 , Issue.4 , pp. 449-460
    • Johnson, B.F.1    Clay, T.M.2    Hobeika, A.C.3
  • 237
    • 79952281184 scopus 로고    scopus 로고
    • Angiogenesis and immunity: A bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy
    • Tartour E, Pere H, Maillere B, et al. Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev. 2011;30(1):83-95.
    • (2011) Cancer Metastasis Rev. , vol.30 , Issue.1 , pp. 83-95
    • Tartour, E.1    Pere, H.2    Maillere, B.3
  • 238
    • 77955406159 scopus 로고    scopus 로고
    • Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer
    • Shrimali RK, Yu Z, Theoret MR, et al. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res. 2010;70(15):6171-6180.
    • (2010) Cancer Res. , vol.70 , Issue.15 , pp. 6171-6180
    • Shrimali, R.K.1    Yu, Z.2    Theoret, M.R.3
  • 239
    • 34447117552 scopus 로고    scopus 로고
    • A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism
    • Manning EA, Ullman JG, Leatherman JM, et al. A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. Clin Cancer Res. 2007;13(13):3951-3959.
    • (2007) Clin Cancer Res. , vol.13 , Issue.13 , pp. 3951-3959
    • Manning, E.A.1    Ullman, J.G.2    Leatherman, J.M.3
  • 240
    • 84877870613 scopus 로고    scopus 로고
    • Vascular normalization as an emerging strategy to enhance cancer immunotherapy
    • Huang Y, Goel S, Duda DG, et al. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res. 2013;73(10):2943-2948.
    • (2013) Cancer Res. , vol.73 , Issue.10 , pp. 2943-2948
    • Huang, Y.1    Goel, S.2    Duda, D.G.3
  • 241
    • 80052919974 scopus 로고    scopus 로고
    • Monoclonal antibody blockade of IL-2 receptor {alpha} during lymphopenia selectively depletes regulatory T cells in mice and humans
    • Mitchell DA, Cui X, Schmittling RJ, et al. Monoclonal antibody blockade of IL-2 receptor {alpha} during lymphopenia selectively depletes regulatory T cells in mice and humans. Blood. 2011;118(11):3003-3012.
    • (2011) Blood , vol.118 , Issue.11 , pp. 3003-3012
    • Mitchell, D.A.1    Cui, X.2    Schmittling, R.J.3
  • 242
    • 33845885624 scopus 로고    scopus 로고
    • Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells
    • Fecci PE, Sweeney AE, Grossi PM, et al. Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. Clin Cancer Res. 2006;12(14 Pt 1):4294-4305.
    • (2006) Clin Cancer Res. , vol.12 , Issue.14 , pp. 4294-4305
    • Fecci, P.E.1    Sweeney, A.E.2    Grossi, P.M.3
  • 243
    • 79954559096 scopus 로고    scopus 로고
    • T-cell tolerance and the multi-functional role of IL-2R signaling in T-regulatory cells
    • Cheng G, Yu A, Malek TR. T-cell tolerance and the multi-functional role of IL-2R signaling in T-regulatory cells. Immunol Rev. 2011;241(1):63-76.
    • (2011) Immunol Rev. , vol.241 , Issue.1 , pp. 63-76
    • Cheng, G.1    Yu, A.2    Malek, T.R.3
  • 244
    • 84879104519 scopus 로고    scopus 로고
    • Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors
    • Duraiswamy J, Kaluza KM, Freeman GJ, et al. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res. 2013;73(12):3591-3603.
    • (2013) Cancer Res. , vol.73 , Issue.12 , pp. 3591-3603
    • Duraiswamy, J.1    Kaluza, K.M.2    Freeman, G.J.3
  • 245
    • 84861233216 scopus 로고    scopus 로고
    • Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors
    • Agarwalla P, Barnard Z, Fecci P, et al. Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors. J Immunother. 2012;35(5):385-389.
    • (2012) J Immunother , vol.35 , Issue.5 , pp. 385-389
    • Agarwalla, P.1    Barnard, Z.2    Fecci, P.3
  • 246
    • 84879874041 scopus 로고    scopus 로고
    • Immunomodulatory monoclonal antibodies combined with peptide vaccination provide potent immunotherapy in an aggressive murine neuroblastoma model
    • Williams EL, Dunn SN, James S, et al. Immunomodulatory monoclonal antibodies combined with peptide vaccination provide potent immunotherapy in an aggressive murine neuroblastoma model. Clin Cancer Res. 2013;19(13):3545-3555.
    • (2013) Clin Cancer Res. , vol.19 , Issue.13 , pp. 3545-3555
    • Williams, E.L.1    Dunn, S.N.2    James, S.3
  • 247
    • 84875689651 scopus 로고    scopus 로고
    • Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer
    • Wada S, Jackson CM, Yoshimura K, et al. Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer. J Transl Med. 2013;11:89.
    • (2013) J Transl Med. , vol.11 , pp. 89
    • Wada, S.1    Jackson, C.M.2    Yoshimura, K.3
  • 248
    • 84860436621 scopus 로고    scopus 로고
    • Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castrationresistant prostate cancer: A phase 1 dose-escalation trial
    • van den Eertwegh AJ, Versluis J, van den Berg HP, et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castrationresistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13(5):509-517.
    • (2012) Lancet Oncol. , vol.13 , Issue.5 , pp. 509-517
    • Van Den Eertwegh, A.J.1    Versluis, J.2    Van Den Berg, H.P.3
  • 249
    • 84892866206 scopus 로고    scopus 로고
    • Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma
    • Weber JS, Kudchadkar RR, Yu B, et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol. 2013;31(34):4311-4318.
    • (2013) J Clin Oncol. , vol.31 , Issue.34 , pp. 4311-4318
    • Weber, J.S.1    Kudchadkar, R.R.2    Yu, B.3
  • 250
    • 77749279776 scopus 로고    scopus 로고
    • PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
    • Curran MA, Montalvo W, Yagita H, et al. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA. 2010;107(9):4275-4280.
    • (2010) Proc Natl Acad Sci USA , vol.107 , Issue.9 , pp. 4275-4280
    • Curran, M.A.1    Montalvo, W.2    Yagita, H.3
  • 251
    • 84879777241 scopus 로고    scopus 로고
    • Nivolumab plus ipilimumab in advanced melanoma
    • Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122-133.
    • (2013) N Engl J Med. , vol.369 , Issue.2 , pp. 122-133
    • Wolchok, J.D.1    Kluger, H.2    Callahan, M.K.3
  • 252
    • 77951625266 scopus 로고    scopus 로고
    • Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group
    • Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963-1972.
    • (2010) J Clin Oncol. , vol.28 , Issue.11 , pp. 1963-1972
    • Wen, P.Y.1    Macdonald, D.R.2    Reardon, D.A.3
  • 253
    • 73149092567 scopus 로고    scopus 로고
    • Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria
    • Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412-7420.
    • (2009) Clin Cancer Res. , vol.15 , Issue.23 , pp. 7412-7420
    • Wolchok, J.D.1    Hoos, A.2    O'Day, S.3
  • 254
    • 0037099539 scopus 로고    scopus 로고
    • Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope
    • author reply 3176-3177
    • Wolchok JD, Chapman PB. Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope. J Clin Oncol. 2002;20(14):3176. author reply 3176-3177.
    • (2002) J Clin Oncol. , vol.20 , Issue.14 , pp. 3176
    • Wolchok, J.D.1    Chapman, P.B.2
  • 255
    • 79955667525 scopus 로고    scopus 로고
    • Do we need novel radiologic response criteria for brain tumor immunotherapy?
    • Okada H, Pollack IF. Do we need novel radiologic response criteria for brain tumor immunotherapy?. Exp Rev Neurotherap. 2011;11(5):619-622.
    • (2011) Exp Rev Neurotherap. , vol.11 , Issue.5 , pp. 619-622
    • Okada, H.1    Pollack, I.F.2
  • 256
    • 79953816808 scopus 로고    scopus 로고
    • Immunologic biomarkers as correlates of clinical response to cancer immunotherapy
    • Disis ML. Immunologic biomarkers as correlates of clinical response to cancer immunotherapy. Cancer Immunol Immunother. 2011;60(3):433-442.
    • (2011) Cancer Immunol Immunother. , vol.60 , Issue.3 , pp. 433-442
    • Disis, M.L.1
  • 257
    • 0242329784 scopus 로고    scopus 로고
    • Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: Results of a clinical phase I/II trial
    • Yamanaka R, Abe T, Yajima N, et al. Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br J Cancer. 2003;89(7):1172-1179.
    • (2003) Br J Cancer. , vol.89 , Issue.7 , pp. 1172-1179
    • Yamanaka, R.1    Abe, T.2    Yajima, N.3
  • 258
    • 84881024704 scopus 로고    scopus 로고
    • A harmonized approach to intracellular cytokine staining gating: Results from an international multiconsortia proficiency panel conducted by the Cancer Immunotherapy Consortium (CIC/CRI)
    • McNeil LK, Price L, Britten CM, et al. A harmonized approach to intracellular cytokine staining gating: Results from an international multiconsortia proficiency panel conducted by the Cancer Immunotherapy Consortium (CIC/CRI). Cytometry A. 2013;83(8):728-738.
    • (2013) Cytometry A. , vol.83 , Issue.8 , pp. 728-738
    • McNeil, L.K.1    Price, L.2    Britten, C.M.3
  • 259
    • 74349117866 scopus 로고    scopus 로고
    • Gamma interferon-mediated superinduction of B7-H1 in PTEN-deficient glioblastoma: A paradoxical mechanism of immune evasion
    • Han SJ, Ahn BJ, Waldron JS, et al. Gamma interferon-mediated superinduction of B7-H1 in PTEN-deficient glioblastoma: a paradoxical mechanism of immune evasion. Neuroreport. 2009;20(18):1597-1602.
    • (2009) Neuroreport , vol.20 , Issue.18 , pp. 1597-1602
    • Han, S.J.1    Ahn, B.J.2    Waldron, J.S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.